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Tensiometrys a complicated mixture of approximately 90% lipids and 10% proteins. It plays an
important role in maintaining normal respiratorymechanics by reducing alveolar surface tension to near-zero
values. Supplementing exogenous surfactant to newborns suffering from respiratory distress syndrome (RDS),
a leading cause of perinatal mortality, has completely altered neonatal care in industrialized countries.
Surfactant therapy has also been applied to the acute respiratory distress syndrome (ARDS) but with only
limited success. Biophysical studies suggest that surfactant inhibition is partially responsible for this
unsatisfactory performance. This paper reviews the biophysical properties of functional and dysfunctional PS.
The biophysical properties of PS are further limited to surface activity, i.e., properties related to highly dynamic
and very low surface tensions. Three main perspectives are reviewed. (1) How does PS permit both rapid
adsorption and the ability to reach very low surface tensions? (2) How is PS inactivated by different inhibitory
substances and how can this inhibition be counteracted? A recent research focus of using water-soluble
polymers as additives to enhance the surface activity of clinical PS and to overcome inhibition is extensively
discussed. (3) Which in vivo, in situ, and in vitro methods are available for evaluating the surface activity of PS
and what are their relative merits? A better understanding of the biophysical properties of functional and
dysfunctional PS is important for the further development of surfactant therapy, especially for its potential
application in ARDS.
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The entire alveolar surface of mammalian lungs is lined with a thin
ﬂuid continuum, called the alveolar lining layer [1]. This lining
consists of an aqueous hypophase covered by a ﬁlm of pulmonary
surfactant (PS) [2]. The major function of this PS ﬁlm is to reduce the
surface tension of the alveolar surface, thereby contributing signiﬁ-
cantly towards maintaining the normal mechanics of respiration [3].
First by lowering alveolar surface tension, PS reduces the energy
required to inﬂate the lungs thereby increasing pulmonary compli-
ance (i.e., the ratio of lung volume change to an applied distending
pressure). Second by decreasing elastic recoil, PS reduces the like-
lihood of alveolar collapse during expiration. As a result, the lungs can
easily maintain patency with a small transpulmonary pressure of less
than 10 cm H2O [4].
PS exists not only in alveoli, but also in bronchioles and small
airways. Themain function of airway surfactant is to maintain patency
of the conducting airways, i.e., to prevent cohesion of bronchiolar
walls by keeping thewater lining spread out and by decreasing surface
tension of the airway mucus lining [5,6]. This latter function is
particularly important in diving mammals (e.g., seals) and in reptiles
because these animals often collapse part, or all, of their lungs as part
of their diving and expiratory cycles [7,8]. When it comes to humans,
PS can play an important role in protecting the epithelial cells from
damage by air thrusts during reopening of collapsed airways, a
common condition in mechanical ventilation [9]. In addition to theTable 1
Physiological functions of pulmonary surfactant
Surface tension related Non-surface tension related
Maintaining a large gas transfer area Speciﬁc and non-speciﬁc host defense
Increasing lung compliance on inspiration Pathogen barrier
Stabilizing alveoli on expiration Antibacterial/antiviral activity
Airway stabilization Smooth muscle relaxation
Anti-edema effects
Anti-adhesion agent
Protecting epithelial cells in airway reopening
Facilitating mucociliary transport
Fluid dispersal
Particle removalclassical functions relevant to surface tension reduction, PS possesses
a number of other functions which make it physiologically indispens-
able. These functions are summarized in Table 1 [10–13]. Nevertheless,
this review will be restricted to the surface tension-relevant proper-
ties of alveolar PS.
Deﬁciency or dysfunction of PS causes severe respiratory disease.
Neonatal respiratory distress syndrome (RDS), the major disease of PS
deﬁciency worldwide, is due to prematurity [14]. Premature infants
suffering from RDS exhibit increased work of breathing, decreased lung
compliance, prominent atelectasis (alveolar collapse) with reduced
functional residual capacity (FRC, i.e., the lung volume remaining at the
endof expiration), impaired gas exchange, and diffuse interstitial edema
[14]. The actual incidence of RDS in premature infants declines greatly
with increasing gestational age. It is estimated that RDS generally affects
10% of all premature infants in developed countries [15]. In 2002 RDS
affected an estimated 24,000 newborns in the USA alone [15].
Displaying symptoms similar to RDS, acute lung injury (ALI) and its
more severe form, the acute respiratory distress syndrome (ARDS),
occur as a rapid onset of respiratory failure that can affect patients of
any age [16]. ARDS affects approximately 150,000 people per year in
the USA and has a case fatality rate of approximately 30–40% [17]. The
pathogenesis of ARDS is still not fully understood but surfactant
inhibition, due to leakage of a variety of inhibitory substances (e.g.,
serumproteins, hemoglobin, and certain lipids) into the alveolar space,
is believed to be an operative cause induced by primary pathogenesis
such as extensive lung inﬂammation, trauma, severe pulmonary
infection, near-drowning, oxygen toxicity, or radiation damage [16,17].
Exogenous surfactant replacement therapy, in which either
synthetic or modiﬁed natural PS (extracted from bovine or porcine
sources) is delivered into the patients' lungs, has been established
as a standard therapeutic intervention for patients with RDS [18].
Surfactant therapy has also shown limited positive effects with ARDS
patients [11,19–21].
Therefore, the study of PS has not only physiological but also
clinical signiﬁcance. This paper reviews the history and recent
progress in PS research. Due to the interdisciplinary nature of these
studies, a large body of literature in a variety of areas including
biochemistry, biophysics, physiology, colloid and interface science,
biomedical and clinical applications, is available. This reviewwill focus
on the biophysical properties, especially surface activity, of PS. Other
1949Y.Y. Zuo et al. / Biochimica et Biophysica Acta 1778 (2008) 1947–1977areas closely related to the biophysical studies are also covered, albeit
to a lesser extent. The remainder of this paper is organized into the
following three parts: (1) Fundamentals of PS, including a brief history
of the discovery of PS and its clinical applications, alveolar surfactant
metabolism, component functionality, and interfacial properties. The
focus of this part is on the biophysical properties of functional PS.
(2) Clinically used PS preparations and the challenge of ARDS treat-
ment. We will emphasize biophysical inhibition of PS and the reversal
of this inhibition by water-soluble polymeric additives, a recent
research focus in developing inactivation-resistant surfactant formu-
lations. (3) Methods for evaluating the surface activity of PS. Although
in vivo, in situ and in vitro methods will be discussed, focus will be on
the in vitro methodologies.
2. Fundamentals of pulmonary surfactant
2.1. A brief history of the discovery of surfactant and its clinical applications
The initial indication for PS can be traced to 1929 when von
Neergaard ﬁrst demonstrated the importance of interfacial forces for
lung mechanics [22]. By comparing the recoil pressure (i.e., the
tendency to collapse) of lungs ﬁlled with air and lungs ﬁlled with
aqueous solution, von Neergaard demonstrated that alveolar surface
tension contributed signiﬁcantly to lung recoil. He also hypothesized
that the alveoli might contain a special surface active material capable
of lowering alveolar surface tension. However, he was not able to
demonstrate that surface active materials were present in the lungs,
using the methods available to him [23].
von Neergaard's ﬁndings drew little attention. In 1955, Pattle
reported in his classic paper, published in Nature [24], that small
bubbles generated in lung extracts initially decreased in size but then
stabilized at 40–50 μm diameter. Pattle concluded that the surface
tension of these microbubbles likely fell to near 0 mN/m. Otherwise
the pressure difference across the bubble interface, predicted by the
Laplace equation of capillarity (see Section 4), would cause the
bubbles to deﬂate rapidly. Initially, Pattle erroneously concluded that
the ﬁlm responsible for the zero surface tension was composed of an
insoluble protein. Pattle later corrected this error by identifying the
ﬁlm as a lipid–protein complex [25].
In 1957, Mead et al. reported the dependence of lung compliance
on surface tension forces [26]. They observed that, when an excised
lung was ﬁlled with air, the quasi-static (step-by-step) transpulmon-
ary pressure observed during inﬂation was higher than that observed
during deﬂation, a phenomenon they called “pulmonary volume–
pressure hysteresis”. The hysteresis largely disappeared with lungs
ﬁlled with saline. They attributed this difference to the effect of
surface tension forces operating at the air–water interface of the lung.
Interestingly, they noted a large discrepancy (∼10-fold) between the
surface area predicted by their measurements (assuming alveolar
surface tension to be 60 mN/m as with serum) and the surface area
calculated by histology.
Also in 1957, Clements published the ﬁrst direct surface tension
measurements on lung extracts using his modiﬁed Langmuir balance
(see Section 4) [27]. He found that the surface tension of saline
extracts from animals' lungs decreased from 46 to 10 mN/mwhen the
surface area was reduced. He also calculated the compressibility of
these ﬁlms to be as low as 0.01 (mN/m)−1, consistent with a strong
ability to stabilize the lungs against collapse at the end of expiration.
This in vitro surface activity of PS, i.e., its ability to decrease surface
tension to remarkably low values upon ﬁlm compression, was later
conﬁrmed by Schurch et al. in situ through direct surface tension
measurements in excised lungs [28].
The clinical correlation between PS deﬁciency and RDS was ﬁrst
established by Avery andMead in 1959 using a Clements-type Langmuir
balance [29]. They reported that very little surface active material could
be recovered from the lungs of infants who died of hyaline membranedisease, now known as RDS. However, surfactant was found in lung
extracts of infantswhodied fromnonpulmonary diseases, provided that
their birthweight wasmore than 1000 g. Avery andMead hypothesized
that the lack of surfactant due to prematurity was responsible for RDS.
The pathological relationship between prematurity and surfactant
deﬁciency was later conﬁrmed by Brumley et al. who found that the
PS system does not mature until late in gestation [30].
In 1980, Fujiwara et al. reported the ﬁrst successful trial of sur-
factant replacement in RDS infants using a surfactant extracted
from bovine lungs [31]. Since that discovery, surfactant replacement
therapy has become a standard therapeutic intervention for RDS
patients. Partially owing to surfactant therapy, the mortality rate of
premature infants in the USA due to RDS fell by 24% in 1990 and has
continued to decrease thereafter [32,33].
In 1967, Ashbaugh et al. ﬁrst described a syndrome of acute
respiratory distress in adults which displayed some symptoms similar
to RDS in premature infants [34]. This syndrome is now referred to as
ARDS. Inspired by the symptomatic similarity between ARDS and RDS,
surfactant replacement therapy has been tested in treating ARDS [35].
It was found that surfactant therapy generally showed a positive effect
on the respiratory aspects of ARDS [19,20,36]. Gaseous exchange is
normally improved in the patients, although the effects on the disease
as a whole can be variable and are largely dependent on dosing,
administration, timing and the actual surfactant preparation used
[37,38]. However, ARDS is a complicated disease which can affect non-
respiratory systems, such as liver and kidney, leading to multiorgan
failure [37,38]. With the exception of two trials conducted with
pediatric patients suffering from a selected etiology consistent with
direct lung involvement and using a highly surface active, modiﬁed
natural surfactant (Infasurf) [39,40], surfactant treatment has not
demonstrated a signiﬁcant impact onmortality fromARDS. As a result,
clear indications of a distinct surfactant-mediated decrease in
mortality or improvement in ventilatory care of ARDS patients are
still lacking and further deﬁnitive clinical trials, possibly using
“designer” surfactant preparations (see Section 3), are required.
Excellent reviews on the history of the discovery of PS and its
clinical applications can be found elsewhere [23,41–46].
2.2. Alveolar surfactant metabolism
Using electron microscopy, Weibel and coworkers [2,47,48] have
convincingly demonstrated that a substantial area of the alveolar sur-
face is lined with a thin aqueous layer. The overall continuity of this
lining layer was deﬁnitively established by studies on rat lungs using
low-temperature electron microscopy [49]. It was found that the
aqueous layer has an average thickness of 0.14 μm over the alveolar
surface, 0.89 μm in alveolar corners, with an overall area-weighted
average thickness of 0.2 μm [49]. Although very thin, this aqueous
layer is considerably larger than that required to accommodate a bulk
phase comparable to the surfactant ﬁlm on top, which is in molecular
dimensions. This aqueous subphase is essential for PS metabolism
because it provides a medium for surfactant secretion, morphological
transformation, adsorption, desorption and recycling [14]. These events
are commonly referred to as the life cycle or alveolar metabolism of
PS [3].
PS is synthesized by pulmonary type II epithelial cells, processed
and packed into lamellar bodies, structures consisting of closely
packed multiple bilayers. Subsequently, PS is secreted into the
aqueous subphase of the alveoli, where the lamellar bodies undergo
transformation into a morphological form called tubular myelin. The
formation of tubular myelin is dependent on the presence of sur-
factant apoproteins and calcium [50–52]. Tubular myelin is composed
of large square elongated tubes, constituted primarily of phospholi-
pids and proteins, ranging in size from nanometers tomicrons [53,54].
It appears that the surfactant components are subsequently released
from tubular myelin to form a surface active ﬁlm at the air–water
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been considered to be a monomolecular ﬁlm, i.e., a monolayer [55,56].
However, accumulated evidence from studies using electron micro-
scopy [57–59], captive bubble tensiometry [59–61], autoradiography
[62], atomic force microscopy [63,64], and neutron reﬂection [65] all
suggest that at least part of the PS ﬁlm is thicker than a single
monolayer. It consists of a surface monolayer plus, in places, one or
more lipid bilayers, closely and apparently functionally associated
with the interfacial monolayer. These multilayers form the so-called
surface-associated “surfactant reservoir” (detailed later) [60].
After de novo adsorption, the surfactant ﬁlm is periodically com-
pressed and expanded during breathing. This action modulates
surface tension in the lungs. After performing its physiological
functions, surfactant is released as small, unilamellar vesicles. Some
of this spent surfactant is taken up by the alveolar macrophages
while most of the remainder is cleared from the alveolar space by
endocytosis back into type II cells. These cells recycle part of the
surfactant components into lamellar bodies. Some surfactant appar-
ently ﬂows into the tracheae and is eventually swallowed. The
estimated turnover period of PS is surprisingly short, ranging from4 to
11 h [66]. Reviews on the metabolism of PS can be found in [67,68].
2.3. Surfactant composition
Comparative biological studies suggest that PS exists in all air-
breathing vertebrates, although with somewhat differing composi-
tions [69–71]. However, the composition of mammalian PS is
remarkably similar among diverse species, i.e., approximately 90%
lipids and 10% proteins by weight [72]. The composition of bovine
surfactant, as shown in Fig. 1, is representative of most species [73].
The lipids consist mainly of phospholipids (PL, ∼90–95 wt.%) with a
small amount of neutral lipids (∼5–10 wt.%), primarily cholesterol
[68,74]. Among the PL components, phosphatidylcholine (PC) is the
most prevalent class, accounting for ∼80% of the total PL. Although
notable exceptions exist [70], in most cases about 30–60% of the PC is
dipalmitoyl phosphatidylcholine (DPPC) (16:0/16:0 PC), a long-chained,
disaturated, zwitterionic PL. Most species also contain signiﬁcant levels
of palmitoyl–myristoyl phosphatidylcholine (PMPC) (16:0/14:0 PC) [70].
The other prominent PC components are mainly unsaturated, e.g.,
palmitoyl–oleoyl phosphatidylcholine (POPC) (16:0/18:1 PC). Apart
from PC, other classes of PL which constitute the remaining 20% are
primarily unsaturated, including mainly anionic PL (e.g., phosphatidyl-
glycerol (PG), phosphatidylinositol (PI), and lyso-bis-phosphatidic acid)
but also including non-PC zwitterionic PL (e.g., phosphatidylethanola-
mine (PE) and sphingomyelin). Anionic PL as a group accounts for ∼15%
of the total PL. Small amounts of lyso-PC are also present.Fig. 1. The composition of bovine pulmonary surfactant. DPPC: dipalmitoyl phosphati-
dylcholine; PC: phosphatidylcholine; PG: phosphatidylglycerol; PI: phosphatidylinositol;
PE: phosphatidylethanolamine; Lyso-bis-PA: lyso-bis-phosphatidic acid; SPM: sphingo-
myelin; DG: diacylglycerol; Chol: Cholesterol. Adapted from Yu et al. [73].Four proteins have been found associated with PS [75]. They are
named surfactant protein (SP)-A, -B, -C and -D, based on the nomen-
clature proposed by Possmayer [76,77]. SP-A (monomeric MW 26–
38 kDa) and SP-D (43 kDa) are large, multimeric, hydrophilic
glycoproteins. They are members of the Ca2+-dependent carbohy-
drate-binding collectin (collagen-like lectin) family. In contrast, SP-B
(MW 8.7 kDa) and SP-C (4.2 kDa) are smaller and extremely
hydrophobic. Among these surfactant associated proteins, SP-A is
the most abundant by mass, accounting for about 5 wt.% of PS, with
SP-D, accounting for about 0.5%. SP-B and SP-C together constitute
approximately 2% (∼1:3 in bovine surfactant).
SP-A is the most abundant surfactant protein by mass, but not in
terms of molar ratio. Taking bovine surfactant as an example, for every
SP-A octadecamer (composed of six trimers) there are approximately
3 SP-B dimers, 45 palmitoylated SP-C and 12,500 PL molecules. There
are about half as many SP-D dodecamers (composed of four trimers)
as SP-A octadecamers in the alveolar space, but SP-D is soluble and
only a small proportion of this collectin will be associated with
surfactant.
Reviews on the PL and protein compositions of PS and its
component functionality can be found elsewhere [10,14,74,75,78–84].
2.4. Phospholipid phase behavior
Discussion of the biophysical properties of PS requires some basic
knowledge of PL phase behavior. The phase behavior of PL is
commonly studied with monolayers, bilayers, or vesicles [85]. The
phase behavior of PL can be profoundly varied by the addition of
cholesterol. Here, we brieﬂy review the PL and PL-cholesterol phase
behavior and lipid polymorphism relevant to PS study. Recent reviews
on the PL phase behavior of bilayers [84], monolayers [86], vesicles
[87], and lipid polymorphism [88,89] can be found elsewhere.
2.4.1. Bilayers
When dispersed in aqueous phase, at room temperature and
atmospheric pressure, most PLmolecules spontaneously form bilayers
(Fig. 2(a)), where the hydrophobic PL fatty acid groups shield each
other from being exposed to water. The formation of closed vesicles
(i.e., liposomes, Fig. 2(b)–(d)) completes this water-avoidance process,
resulting in energetically optimized structures. With increasing
temperature, PL bilayers without cholesterol “melt” from an ordered
gel (Lβ) phase to a disordered liquid–crystalline (Lα) phase at the main
transition temperature (Tm). This fatty acid disorder permits diffusion
of individual PL molecules within each leaﬂet of the bilayer, a property
referred to as “ﬂuidity”.
Addition of a sterol such as cholesterol transforms PL bilayers in Lβ
and Lα phases into a liquid-ordered (Lo) phase (sometimes referred to
as β phase) and a liquid-disordered (Ld) phase, respectively. The
overall ﬂuidity of the bilayers in the above mentioned four phases
would be LβbLobLdbLα. This is because when intercalated between
the closely packed Lβ PL molecules, cholesterol disrupts (ﬂuidizes) the
ordered structures. On the other hand, when associated with mobile
Lα PL molecules, cholesterol condenses and increases the packing
density of the disordered structure [90]. Thus the overall effect of
cholesterol is to have a ﬂuidizing effect on lipids in the gel state
(because it disrupts packing) and a condensing effect on ﬂuid
membranes (because it interacts with disordered chains and stabilizes
them). However, the actual phase behavior of PL-cholesterol mixtures
is complex and depends greatly on both the temperature and
cholesterol mol fraction [91].
The readers are cautioned that some authors have not yet adopted
the above nomenclature and may, for example, refer to plasma
membrane lipids, which contain cholesterol, as being in the Lα phase.
It should also be noted that the actual phase behavior of PL bilayers
can be more complicated and intermediate phases, such as the ripple
phase, can exist between the main Lβ and Lα phases [85].
Fig. 2. Different phospholipid (PL) morphology in the aqueous phase. The formation of bilayer and nonbilayer structures is largely dependent on the molecular shape of the PL.
(a)–(d) show bilayer structures and (e)–(g) show a nonbilayer structure. (a) Cross section of a PL bilayer, where the fatty acids interact and the hydrophilic headgroups are
close together to help keep the acyl moieties “dry”. There is an inherent positive curvature with bilayers which is exaggerated here; (b) Unilamellar vesicle, which is similar in
form to a tennis ball; (c) Multilamellar vesicle, which is similar to an onion; (d) Multivesicular body, where small vesicles are trapped within a larger vesicle; (e)–(g) Inverted
hexagonal (HII) phase. (e) Cross section of a HII phase cylinder. Due to the small size of the PE headgroup, with a planar bilayer the mobile acyl groups would be exposed to water.
Moving the headgroups together results in negative curvature of the resulting cluster. As a consequence the PE headgroups enclose a water pocket and the acyl groups extend
outwards. (f) A HII phase cylinder, where the PE headgroups interact with the long column of water extending down the middle of the cylinder. Note that only two methyl groups
per PE molecule are exposed to the exterior. (g) HII phase, where a number of the hydrophobic cylinders depicted in (f) interact together in a hexagonal pattern, thus minimizing
water–fatty acid interactions.
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With PLmonolayers, water avoidance is achieved through extension
of the fatty acid groups into the air (which is much more hydrophobic
than water). The behavior of PL in interfacial monolayers can be
correlated at least in part with the phase behavior of hydrated bilayers.
Deposition of a small amount of a saturated PL, such as DPPC, on a
surface balance will result in a monolayer in the dilute gaseous phase.
Because van derWaals attractive forces areweak and the fatty acids can
“wave” in air, theDPPCmolecules can collidewith one another, although
they tend to remain separated. Reducing the surface area available to
each lipid molecule by moving a barrier across the surface or by
depositing additional DPPC will increase the surface concentration. At a
certain point, all of the molecules will touch each other. A further
compression will then lead to a detectable increase in surface pressure,
which can be measured either as back pressure on the barriers of a
surface balance or, as explained later, as a decrease in surface tension.
Here PLmolecules will no longer be in the dilute gaseous state but are in
the more concentrated lipid-expanded (LE) phase where they interact,
but the fatty acids remainmobile due to the presence of kinked gauche–
gauche (also known as trans-gauche) conﬁgurations.
As the ﬁlm is further compressed, some of the PL molecules will
become more closely packed to generate the more ordered tilted-
condensed (TC) phase (traditionally called the liquid-condensed (LC)
phase) where all of the acyl groups are in the extended all-trans
(straight) conﬁguration [86]. At this point, further decreases in surface
areawill generate LE-TC coexistence where the decreased surface area
is taken up by forming a greater proportion of TC phase [86,92–94].
Nucleation and growth of the TC phase in PL monolayers can be
directly visualized as “domain” formation using ﬂuorescence micro-scopy or atomic force microscopy (AFM) (detailed later). Within the TC
domains, PL molecules interact side by side and the fatty acids tilt in a
parallel fashion with a tilting angle smaller than the PL molecules in
the LE phase. (See Fig. 3(b) for a schematic of the different chain tilting
in the LE and TC phases.) Withmonolayers composed of free saturated
fatty acids, further pressure (area reduction) can lead to a solid phase,
also known as the untilted-condensed phase [86], in which the fatty
acid chains are nearly perpendicular to the surface. Theoretically, this
could also occur with DPPC, possibly by dehydration and reorientation
of the phosphorylcholine headgroups, but to our knowledge, there is
no direct experimental evidence for the formation of the solid phase
with either DPPC or PS [93,94].
The domain formation occurring during LE-TC phase transition due
tomonolayer compression can be considered as a process of pressure-
induced crystallization. This raises a distinction between phase transi-
tion in monolayers and bilayers. While (bulk) pressure has only a
small effect on bilayers, phase transition in monolayers is dependent
not only on temperature but also on the surface pressure of the
monolayers. With a monolayer in the LE-TC coexistence state, in-
creasing the temperature will lead to a reduction in the size and
possibly the number of the TC domains. However, simply increasing
the surface pressure will restore the domains. This is true for
temperatures up to and, in practice, somewhat above the correspond-
ing Tm for bilayers of that particular PL [92,94–98]. For example, it has
been observed that highly compressed DPPC monolayers only melted
at temperatures of 48–55 °C, well above the DPPC bilayer Tm of 41.5 °C
[97]. In essence, this means that compared to bilayers, monolayers do
not possess a characteristic Tm. Rather, the “Tm” for monolayers is
highly dependent on the surface pressure.
Fig. 3. Schematic representation of pulmonary surfactant adsorption. (a) Diffusion of a surfactant vesicle/bilayer towards the air–water interface. In this schematic, the surfactant
bilayers consistmainly of DPPC,ﬂuid PC (such as POPC), PG (DPPG and POPG) and PE, in similar proportion to BLES. (b) Fusion of the vesicle/bilayerwith the interface stabilized by SP-B.
Note that PE molecules could help stabilize the negative curvature generated at the fusion pore/neck monolayer and fusion pore bilayer interfaces. The monolayer contains tilted-
condensed (TC) and liquid-expanded (LE) domains composed of saturated and unsaturated phospholipids, respectively. (c) Fusion of the vesicle/bilayerwith the interface stabilized by
SP-C. Note that the bilayer can be also connected to the interfacial monolayer by a SP-C molecule. Such SP-B and SP-C stabilized fusion necks/pores can occur simultaneously and
independently during the adsorption of surfactant. Note that SP-B and SP-C are not drawn to scale and the proportions of these hydrophobic proteins to PL are not representative.
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monolayer changes the TC phase to a liquid-ordered (LO) phase,
whereas adding this sterol to an unsaturated POPC monolayer
converts it to a liquid-disordered (LD) phase. The LO phase is more
ﬂuid than the TC phase and the LD phase is less ﬂuid than the LE phase,
leading to an order of ﬂuidity: TCbLObLDbLE.
2.4.3. Nonbilayer phases
In addition to bilayer structures, certain PL molecules upon
hydration can self-assemble into some nonbilayer structures, such
as the inverted hexagonal (HII) phase (Fig. 2(e)–(g)) and cubic phases[88,89,99]. These nonbilayer phases have a curved morphology which
contrasts with the planar morphology of lamellar phases. As shown in
Fig. 2(g), in HII phase, PL molecules are arranged cylindrically with the
polar headgroups facing toward the interior of the structure. The
formation of nonbilayer phases arises due to the molecular shape of
the PL [88,89,99]. Typical bilayer-forming molecules, such as PC, both
solid and ﬂuid, have a cylindrical shape with nearly equal headgroup
and hydrocarbon areas. Such molecules pack into sheets which can ﬁt
readily into bilayers. In contrast, nonbilayer-forming lipids, such as
ﬂuid PE, exhibit a cone-shape with a small headgroup area and large
hydrocarbon area. This molecular shape prevents them from packing
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between the headgroups and wetting the acyl groups. Consequently,
monolayers comprised of such lipids have a spontaneous tendency to
form structures with negative curvature [100].
Formation of HII phase is promoted by increasing the temperature,
introducing acyl chain unsaturation, and decreasing pH [101,102].
Unsaturated PE is found to be particularly effective in forming HII
phase [89]. In addition, certain proteins or peptides are found to
modulate the tendency of lipids to form HII phase [88]. The nonbilayer
phases, such as the HII phase, have found particular interest in the
study of membrane fusion [89,103].
2.5. Biophysical properties
At least three biophysical properties of PS are considered essential
for normal respiratory physiology, especially in the neonatal period.
These are: (1) rapid adsorption, (2) very low surface tension upon ﬁlm
compression, and (3) effective ﬁlm replenishment upon ﬁlm expan-
sion [3,84,104,105].
2.5.1. Rapid adsorption
A functional PS should adsorb rapidly to form a ﬁlm at the air–
water interface of the lungs, probably within a few seconds or faster.
Analogous to bilayer fusion, the adsorption of surfactant aggregates
to an air–water interface likely consists of two sequential steps
[106–109]. As shown in Fig. 3(a), the surfactant aggregates must ﬁrst
diffuse to the subphase closely adjacent to the interface. This diffusion
step is highly dependent on the surfactant concentration in the
subphase [110,111]. In the second step, as shown in Fig. 3(b) and (c),
the surfactant aggregates need to fuse with the interface. This fusion
step involves “unzipping” and spreading of the surfactant PL vesicles
at the interface. Although PL vesicles are held together by weak van
der Waals forces, the major cohesive force arises from the so-called
hydrophobic effect, because considerable energy is conserved through
the formation of vesicles. Therefore, unzipping of PL vesicles needs to
overcome an energy barrier, which arises during unravelling of the PL
vesicles in water, before the hydrophobic fatty acid chains become
exposed to the atmosphere [106,107]. Not surprisingly, adding ﬂuid PL
to DPPC decreases the energy barrier as they increase overall disorder.
Anionic PL such as ﬂuid PG has been shown to be particularly effective.
However, recent studies indicate that with either native or modiﬁed
PS, or the lipids derived from surfactant, the factors mentioned above
play only a small role. Rather, it appears that the formation of a fusion
neck or pore, perhaps similar to those observed with viral membrane
cell fusion or bilayer fusion, contributes even more to the adsorption
process [101,102]. For example, addition of lyso-PC, which should
increase disorder but would hinder the formation of negatively curved
structures with concave hydrophilic faces as present in fusion necks,
markedly prolongs adsorption times [112].
Addition of SP-B and SP-C counteracts the energy barrier limiting
adsorption, especially in the presence of anionic PL (such as PG),
possibly by introducing electrostatic interactions [107,109,113]. SP-B
and SP-C signiﬁcantly promote adsorption [107,109,113] and reinser-
tion of PL vesicles from the surfactant multilayers into the interfacial
monolayer during ﬁlm expansion [114]. Perhaps the most effective
way for SP-B or SP-C to promote adsorptionwould be to stabilize neck
structures (as shown in Fig. 3(b) and (c)) [101,115]. However, to date,
direct evidence, for example by microscopy or by demonstrating the
presence of negatively curved structures such as the HII phase, is still
lacking [112].
During adsorption, ﬁlms of a physiologically competent surfactant
can decrease the surface tension of the air–water interface from
∼70 mN/m to ∼20–25 mN/m at 37 °C, but no further [84]. At this ﬁnal
surface tension range, the PLmolecules at the air–water interface are in
thermodynamic equilibriumwith themolecules in the bulk phase [84].
This equilibrium surface tension (γeq) corresponds to the equilibriumspreading pressure (πe) of PL, which is the highest surface pressure
obtained by spreading excess saturated or unsaturated PL at the air–
water interfacewith organic solvent or by placing dry crystals of the PL
at the interface [84]. Increases in surface pressure beyond πe can only
be achieved at a ﬁxed temperature by lateral ﬁlm compression.
It should be noted that surface pressure (π) and surface tension (γ)
are linearly correlated by
p = g0−g ð1Þ
where, γ0 is the surface tension of a clean air–water interface at the
experimental temperature, approximately equal to 70 mN/m at 37 °C.
Thus, π corresponds to the extent that a ﬁlm decreases γ. Surface
tension, γ, with quantitatively equivalent units of mN/m or mJ/m2, is
commonly used in lung physiology and biology as a measure of the
energy used to create a unit area of a new interface in air. The γ of a
liquid can be directly measured by monitoring the shape of a sessile or
pendant drop of the liquid (detailed in Section 4). Alternatively, γ can
be measured from the additional force exerted on a suspended plate
or other object due to capillary rise, upon contact with the liquid
surface as, for example, with the Wilhelmy plate or the Du Noüy ring
method [116].
Surface pressure, π, is the concept usually used in the physical
chemistry of monolayers where surface energy is interpreted in terms
of intermolecular forces [117]. The original Langmuir balance
measured π directly using a barrier connected to a pressure transducer
[118]. π is a more fundamental concept under this circumstance as it
offers the direct 2D monolayer analog of the bulk phase (3D) pressure.
As a result, many equations of state derived for the bulk phase can be
directly applied tomonolayers without signiﬁcant reformatting. In the
remaining part of this review, both γ and πwill be used dependent on
convenience and clarity, with the corresponding value included,
where deemed helpful to the reader.
2.5.2. Film stability at low surface tensions
Although limited, the available experimental evidence indicates
that γ of the alveolar surface falls to very low values during expiration
[28,119–121]. Accordingly, upon compression, competent PS ﬁlms
should lower γ to near-zero values [119], in other words, increase π to
a value close to 70mN/m at 37 °C. Equally important, this low γ should
be achieved by only a slight ﬁlm compression, i.e., no more than 20–
30% area reduction, corresponding to the maximum variation of the
alveolar surface area during normal tidal breathing [121,122]. Hence,
the ﬁlm should have a low compressibility (dlnA /dγ) of less than 0.01
(mN/m)−1. Upon expansion, the PS ﬁlm should only moderately
increase γ and remain close to γeq [120]. The complete compression–
expansion loop should have limited hysteresis, reﬂecting minimized
ﬁlm collapse and efﬁcient ﬁlm replenishment.
These premier biophysical properties of PS, however, seemingly
create a paradox. Rapid adsorption requires ﬂuid PL molecules with
highly mobile amphiphilic structures [116]. However, physicochemical
studies have established that monolayers formed by ﬂuid amphi-
philic molecules generally collapse rapidly when π is increased beyond
πe, for example, in a Langmuir balance [123]. To sustain stable (or
metastable) π higher than πe, a monolayer must consist of highly rigid,
insoluble surfactant molecules [117,124]. Experiments with Langmuir
monolayers demonstrate that only such stiff molecules allow the
formation of highly ordered, tightly packed, solid-like ﬁlms in a con-
densed phase, thus being capable of increasing π higher than πe without
monolayer collapse. Fully hydrated DPPC bilayers have a Tm near 41 °C.
Hence, DPPC is traditionally taken to be the only signiﬁcant component
of PS capable of reaching high π at physiological temperatures. This led
to the classical model of surfactant function which suggested that the
alveoli were stabilized by a monolayer highly enriched in DPPC [125–
127]. Note that such a monolayer is in a metastable state, conﬁned by
the πe (∼45 mN/m) and the collapse pressure (∼70 mN/m) of DPPC.
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DPPC bilayers below 41 °C, is very slow. (Actually, dry DPPC will not
adsorb below Tm. This is because PL molecules do not hydrate well
unless the fatty acids of the PL are mobile and this occurs at Tm.) No
single component in endogenous PS is able to both adsorb rapidly and
withstand π higher than πe at 37 °C for a time period long enough to
avoid alveolar collapse. This dilemma has been rationalized by the so-
called “squeeze-out” hypothesis [125–127]. The squeeze-out model
predicts a rapid cooperative adsorption of DPPC and other unsaturated
PL components to the air–water interface in which the unsatisfactory
adsorption of DPPC is compensated for by the presence of unsaturated
PL, neutral lipids, and, most importantly, the surfactant associated
proteins. SP-B and SP-C independently promote rapid adsorption of PL
[75,81]. SP-A further enhances adsorption in the presence of SP-B and
calcium ions [128–131]. These proteins enhance adsorption much
more than the effects of unsaturated PL. The squeeze-out hypothesis
proposed that after adsorption, the ﬂuid non-DPPC components,
which are less effective in lowering γ, are selectively squeezed out of
the ﬁlm during ﬁlm compression. This likely occurs with the help of
SP-B and SP-C [63,64,132–140]. This selective squeeze-out process
would result in a condensed, highly DPPC-enriched ﬁlm that would be
responsible for the further reduction of γ to near-zero values upon
further ﬁlm compression [125–127].
Although theoretically plausible, both the classical model and the
squeeze-out hypothesis have been challenged by recent studies on
monolayer phase transition/separation using direct ﬁlm imaging
[141–149]. As shown in Fig. 4, when examined in a Langmuir balance
at room temperature, pure DPPC monolayers show a plateau of LE-TC
phase coexistence at π of 8–13 mN/m [86]. The TC phase consists of
domains which exclude ﬂuorescent dyes (detected by epiﬂuorescence
microscopy) [86,150] and extend ∼1 nm higher than the LE phaseFig. 4. Compression isotherms and characteristic ﬁlm structures for monolayers of bovine lip
AFM at room temperature. The AFM scan areas for BLES ﬁlms are 20×20 μm and for DPPC ﬁl
and for DPPC (10×10 μm) show the nanometer-sized TC domains. The AFM images of BLES cle
20 to 40mN/m. Nanodomains are observed at 30mN/m and increase in number up to 40mN/
to 40 mN/m. At 50 mN/m, multilayers that contain stacks of PL bilayers appear (see the surfa
reﬂected by the plateau at 40–50 mN/m in the compression isotherm of BLES. In contrast to B
(The kink shown in DPPC isotherm at ∼50 mN/m is likely an artefact due to ﬁlm leakage to t
nanodomains. After this transition region, indicated by the rising plateau in the DPPC isothe
adapted from Zuo et al. [149]. AFM images of DPPC are courtesy of Dr. Eleonora Keating, Un(detected by AFM) [141,151]. At π beyond the plateau region, pure
DPPC monolayers consist of a nearly homogeneous TC phase [86,141].
In contrast, as shown in Fig. 4, LE-TC coexistence in PS monolayers
clearly persists to a π of at least 40 mN/m [141–143,149]. The results
from recent ﬂuorescence microscopy studies have demonstrated that
LE-TC phase coexistence in the PL fraction of PS persists even at π
approaching 70 mN/m (i.e., at near-zero γ) [146]. The TC domains
contain mostly DPPC and small amounts of other disaturated PL such
as DPPG (16:0/16:0 PG) [152] and perhaps PMPC [153], while the LE
domains contain mostly unsaturated components. As revealed by
ﬂuorescence microscopy, the TC domains account for a total area
fraction of 30–40% of the PS ﬁlms, roughly corresponding to the
percentage of disaturated PL [146,147]. These ﬁndings clearly
demonstrate that a TC ﬁlm composed of almost pure DPPC is not
required for reaching high π. This obviously contradicts the classical
model, which contends that a monolayer highly enriched in DPPC
stabilizes the alveoli at end-expiration [125–127].
The question as to how surfactant ﬁlms with mixed LE and TC
domains attain π near 70mN/m remains. The TC domains are enriched
in DPPC and hence are intrinsically stable at high π. However, how the
LE domains, which account for most of the surface area, persist with
high π remains unknown. The most obvious explanation is that with
appropriate Langmuir balances and experimental conditions, the PL
fraction of PS can be compressed into a metastable ﬁlm that acts like a
“solid”, despite being predominantly in a LE phase [146].
A potential explanation for this seemingly paradoxical situation is
that these LE domains may form a sort of matrix in which the TC
domains are uniformly distributed [149,154,155]. This can be
envisioned as a kind of composite material or be analogous to an
alloy [75]. This suggestion is supported by recent studies using AFM.
With a higher resolution than ﬂuorescence microscopy, AFM hasid extract surfactant (BLES) and DPPC, studied by the Langmuir–Wilhelmy balance and
ms are 50×50 μm. The enlargements of the AFM images for BLES at 30 mN/m (1×1 μm)
arly show LE-TC phase separations and transitions as the surface pressure increases from
m; in contrast, microdomains increase in area from 20 to 30mN/m but decrease from 30
ce plot of the AFM image). The transition from a monolayer to multilayers is apparently
LES, DPPC monolayers only show LE-TC phase coexistence and transition at 8–13 mN/m.
he Teﬂon ribbon.) The TC phase in DPPC monolayers also consists of microdomains and
rm, DPPC monolayers consist of nearly homogenous TC phase. AFM images of BLES are
iversity of Western Ontario.
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the LE phase, in DPPC and DPPC/DPPG monolayers [155]. The number
and size of these nanodomains depend on the presence and
concentration of surfactant proteins [155]. Recently, such nanodo-
mains have been demonstrated in a modiﬁed natural surfactant
(bovine lipid extract surfactant, BLES) with and without SP-A [149]. It
was found that when π of BLES ﬁlms was increased, the original
micrometer-sized TC domains (i.e., microdomains) dissociated into
many nanodomains (Fig. 4). As a result, at 40 mN/m the BLES
monolayers contained only a few microdomains but many nanodo-
mains uniformly embedded within the LE phase. The total area of
thesemicroscale and nanoscale TC domains accounted for ∼40% of the
surface area [149], approximately equal to the total fraction of
disaturated PL in BLES [153]. Topographic analysis also suggested
that these nanodomains, similar to their microscale counterparts, are
composed of disaturated PL [149,155]. Due to the composite structure,
such surfactant monolayers could be both ﬂexible and stable.
A second mechanism for attaining high π (low γ) arises from the
3D multilayer structures formed when the composite monolayers are
further compressed beyond a π close to the πe of PL (i.e., 40–45mN/m)
[149]. Such a 3D architecture consists of the interfacial monolayer plus
interconnected bilayers closely associated with the interface (see the
surface plot at 50 mN/m in Fig. 4) [63,149,156,157]. The monolayer-to-
multilayer transition is reﬂected in the compression isotherm of PL
ﬁlms by a plateau at 40–50 mN/m, as shown in Fig. 4. This 3D
architecture could provide additional stability by acting as a skeleton
or scaffold to resist further compression and hence allow the ﬁlms to
attain π above πe [149,154]. This would be particularly true if, as has
been proposed, the excluded multilayers are bridged to the interfacial
monolayer through SP-B and SP-C (see Fig. 3(b) and (c) for schematics)
[136,157–159].
It should be noted that the compression-driven monolayer-to-
multilayer transition generally occurs at a π close to the πe of PL at
which multilayers are formed during adsorption, i.e., the surfactant
reservoir (detailed later). This coincidencemay indicate that these two
multilayer structures are formed due to the same molecular basis, i.e.,
accumulation of excess material at the air–water interface beyond
saturation. In other words, if there is insufﬁcient free surface area to
accommodate the PL in the interfacial monolayer, the excess material
becomes surface-associated multilayers [62,84]. Actually, theoretical
studies have suggested that there may be a slight deviation between
the πe at which 3D nuclei coexist with a 2D monolayer in an adsorbed
ﬁlm and the π at which 3D nucleation initiates in a Langmuir
monolayer during compression [160]. However, such a deviation may
not be distinguishable for a complicated biological system like PS.
Recent molecular dynamics simulations suggested that the compres-
sion-driven multilayer structures could protrude into the aqueous
subphase, as folding bilayers, instead of extending into the air [161].
This further indicated that the multilayer structures formed during
compression appear to be similar, if not identical, to the surface-
associated surfactant reservoir formed during adsorption, both func-
tionally and structurally.
Here, it is important to distinguish the monolayer-to-multilayer
transition occurring at πe from the two other phenomena/hypotheses.
First, it is different from the “true” collapse of PS ﬁlms near π of 70 mN/
m. During the ﬁlm collapse at 70 mN/m, the PL molecules are primarily
irreversibly lost into the bulk phase in the form of small aggregates/
vesicles [162]. Hence further ﬁlm compression causes no increase in π
above the collapse pressure. In contrast, the monolayer-to-multilayer
transition appears to represent a reversible, partial collapse of the
interfacial monolayer occurring near πe. The resultant multilayer
structures apparently remain closely attached to the interfacial mono-
layer as they can readily re-spread to the interfacial monolayer during
ﬁlm expansion [63,149]. Second, themonolayer-to-multilayer transition
is intrinsically different fromthe “squeeze-out”predictedby the classical
model [125–127]. The 40–45 mN/m squeeze-out model mentionedabove predicts that PS ﬁlms maintain stability by selectively excluding
ﬂuid non-DPPC components from the interfacial monolayers. Conse-
quently, the interfacial monolayer after formation of the multilayered
protrusions would be expected to be puriﬁed with DPPC. However,
recent AFM and Kelvin probe force microscopy studies have found that
the topography and electrical surface potential of the interfacial
monolayer appear to be heterogeneous even after the multilayer
formation [157,163]. Hence, the multilayers would appear to show no
absolute differences from the interfacial monolayer in terms of
composition. A similar conclusion has been derived from time-of-ﬂight
secondary ion mass spectrometry (ToF-SIMS) studies of compressed
DPPC/DPPG/SP-C ﬁlms [156]. Autoradiographic studies also indicated
that the lipid composition of multilayers formed during adsorption is
similar to the interfacial monolayer [62].
In addition to the above indicated PL phase transition and
multilayer model based on microscopic studies, another hypothesis
has been proposed by Hall and coworkers to explain how PS
monolayers could reach low surface tensions [147,148,164]. This
group found that monolayers of the PL of PS or a single-component
ﬂuid PL can be transformed to a metastable structure when the
monolayers are compressed to π higher than πe (actually higher than
∼55 mN/m) using a sufﬁciently rapid compression, the so-called
“supercompression”, in a captive bubble surfactometer (CBS)
[164,165]. Once transformed by a supercompression, the physico-
chemical properties of the initial ﬂuid ﬁlms are markedly altered.
These ﬁlms (for example a POPC ﬁlm that usually collapses at πe when
compressed slowly in a Langmuir balance) can withstand high π for
prolonged periods, even if the ﬁlms are expanded back to π below πe
[164,165]. These workers proposed that these ﬁlms are compressed so
quickly that they do not have enough time to collapse near πe, but
rather form an amorphous, non-crystalline structure (termed a “jam”
phase). This can be considered similar to 3D liquids supercooled
towards a glass transition [147,148]. A recent study of the melting
behavior of supercompressed PS, DPPC and POPC monolayers clearly
suggested that a supercompressed PS ﬁlm is different from either a
pure DPPC or a pure POPC monolayer [97,98]. So far, no detailed
microscopic examination of the ﬁlm structure after supercompression
is available, probably due to technical difﬁculties.
It should be noted that the PL phase transition model and the
supercompressionmodel are not necessarily conﬂicting. A recent AFM
study of BLES monolayers, conducted in a Langmuir balance at room
temperature, showed that after a rapid compression (close to the rate
of supercompression for extracted surfactants, deﬁned by Hall et al.,
i.e., ∼4% area per second [147]) the monolayers consisted of mainly
nanometer-sized TC domains [149]. Although only a low π of 30mN/m
was examined [149], this observation suggested an alternative
interpretation of the supercompression model: the rapid compres-
sions likely facilitate formation of TC nanodomains rather than
microdomains because the latter structures require longer times for
assembling. Monolayers containing evenly distributed TC nanodo-
mains could be stable despite containing a large proportion of LE phase
since they could act as an alloy or a composite material, as explained
above. Upon compression, suchmonolayerswould be expected to have
little chance of fracture. Further, should fractures occur at extreme
compression, they would not be readily propagated because they
would have to proceed around the intervening TC nanodomains.
2.5.3. Surface-associated surfactant reservoir
In order to function appropriately in the lung, a competent PS must
be able to maintain a near equilibrium γ during inspiration [28,120].
Dynamic compression–expansion cycling studies conducted with the
pulsating bubble surfactometer (PBS) or the CBS indicate that PL uptake
into the interface occurs too quickly to be explained by de novo
adsorption of PL vesicles from the subphase. Hence this can be best
explained by re-spreading from a surface-associated surfactant reser-
voir, formed during adsorption and/or ﬁlm compression, and
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evidence for the surfactant reservoir came from CBS studies where it
was shown that although bulk phase PS was removed by washing, the
remaining surfaceﬁlmcontainedhighly surface activematerial in excess
of the interfacial monolayer [60]. This concept has been reinforced by
numerous studies using electron microscopy, autoradiography, ﬂuores-
cence microscopy, and AFM, all of which revealed excessive PL material
associated with the surface monolayer [61–65,136,158,166,167].
Although notable exceptions exist, as a general rule, PS preparations
that adsorb well also tend to function well to reduce γ to low values
during ﬁlm compression and to re-spread effectively during ﬁlm
expansion. This correlation likely exists because the surfactant reservoir
can be created during adsorption and situations promoting rapid
adsorption (e.g., high surfactant concentration, presence of SP-A, lack of
inhibitors) favor formation of the multilayered reservoir. Once estab-
lished, the interfacial surfactant monolayer can exchange surface active
material with the surfactant reservoir during ﬁlm compression and ex-
pansion. Although not fully understood, it is evident that SP-B and SP-C
contribute to reservoir formation (as shown in Fig. 3(b) and (c)), most
likely at independent sites, as does SP-A in the presence of SP-B and
calcium [60,62,131,168,169].
In closing Section 2, we would like to emphasize that functional PS
ﬁlms may reach low γ (high π) by forming kinetically-controlled
nanoscale TC domains. These nanodomains are uniformly distributed
in the LE phase, thus forming a 2D alloy-type structure which imparts
both ﬂexibility and stability to the monolayers. Upon further compres-
sion, such an alloy structure also facilitates partial collapse of surfactant
monolayers from the domain boundaries [170,171]. The resultant
multilayer structures could provide additional stability to PSmonolayers,
thereby allowing the attainment of very low γ. It should be evident that
thebiophysical properties of PS, althoughdependenton surfactant PL, are
directed by the surfactant apoproteins SP-B, SP-C, and to a lesser extent
by SP-A. These surfactant proteins inﬂuence the extent of nanodomain
formation. They also facilitate formation of multilayers which act as the
surfactant reservoir. The biophysical performance of PS monolayers is
signiﬁcantly enhanced by the surfactant reservoir. A complete under-
standing of the biophysical properties of PS on a mechanistic level,
however, is still unavailable. Both the classical and the modern modelsTable 2
Surfactant preparations used clinically and preclinically
Trade name Source Manufacturer
Human surfactant containing all surfactant proteins
– Human amniotic ﬂuid –
Modiﬁed natural surfactant containing hydrophobic proteins SP-B and SP-C
Alveofact Bovine lung lavage Boehringer Ingelhei
Ingelheim, Germany
BLES Bovine lung lavage BLES Biochemicals,
Ontario, Canada
Infasurf Calf lung lavage Forest Pharmaceutic
Surfacten Bovine lung mince+DPPC+palmitic acid+tripalmitin Tokyo Tanabe Co., To
Survanta Bovine lung mince+DPPC+palmitic acid+tripalmitin Abbott Laboratories
Curosurf Porcine lung mince Chiesi Farmaceutici,
Synthetic surfactant containing simpliﬁed peptides or protein analogs
Surfaxin SP-B-like peptide (KL4)+ lipids Discovery Laborator
Warrington, PA
Venticute Recombinant SP-C (rSP-C)+lipids Altana Pharmaceuti
Konstanz, Germany
Synthetic surfactant free of proteins
ALEC DPPC+PG Britannia Pharmace
Surrey, UK
Exosurf DPPC+hexadecanol+tyloxapol Burroughs Wellcom
Triangle Park, NC
ALEC: artiﬁcial lung-expanding compound; BLES: bovine lipid extract surfactant.have limitations [147]. Recent reviews on themolecular interactions of PS
components and their contributions to the biophysical properties of PS
ﬁlms can be found elsewhere [105,147,154,172].
3. Inhibition of clinical surfactants and reversal thereof
3.1. Different types of clinical surfactants
A number of exogenous surfactants have been tested in clinical or
preclinical trials for treating RDS and ARDS. As summarized in Table 2,
these therapeutic preparations generally fall into four categories
based on surfactant apoprotein content [11,14,36,173]. They are: (1)
whole surfactant from human amniotic ﬂuid, containing both the
hydrophobic and hydrophilic proteins; (2) modiﬁed natural surfac-
tants derived from either bovine or porcine sources, which contain
only the hydrophobic surfactant proteins SP-B and SP-C (e.g., BLES,
Curosurf, Infasurf and Survanta); (3) synthetic surfactants that contain
simpliﬁed peptides or recombinant surfactant protein analogs (e.g.,
Surfaxin and Venticute); and (4) protein-free synthetic surfactants
that consist of only PL components (mainly DPPC) and additives (e.g.,
ALEC and Exosurf). Among these surfactant preparations, human
amniotic ﬂuid lacks commercial capacity due to its source limitation.
The synthetic surfactants devoid of proteins have become unpopular
due to their relatively poor clinical performance [174]. ALEC, which
was licensed in the UK, has been withdrawn from the market. Exosurf
is no longer available in the USA.
Both preclinical animal experiments and clinical practice suggest
that the animal-derived surfactant preparations are superior to the
synthetic preparations [174–176]. However, these modiﬁed natural
surfactants also have some limitations. The general concerns of
animal-derived products are batch-to-batch variation in composition
and potential risk of transmission of microbes. In addition, the
surfactant protein contents in the modiﬁed natural surfactants
currently available for clinical use can be very low compared with
the endogenous surfactant. Because of immunological considerations,
none of the modiﬁed natural surfactants currently available contains
the hydrophilic proteins (SP-A and SP-D), which are removed during
the puriﬁcation processes used in manufacturing the products. This isAdvantages Disadvantages
• High resistance to inhibition • Not readily available
m Co., • Good biophysical properties • Transmission risk
London, • High resistance to inhibition • Batch-to-batch variation
als, St. Louis, MO
kyo, Japan
, Abbott Park, IL
Parma, Italy
ies, • Completely deﬁned formulation • Under development
• Good biophysical properties • Current preparations are
less effective than modiﬁed
natural surfactants
cals, • High resistance to inhibition
uticals, Redhill, • No risk of disease transmission • Poor biophysical properties
e, Research • Less immunological rejection • Low resistance to inhibition
1957Y.Y. Zuo et al. / Biochimica et Biophysica Acta 1778 (2008) 1947–1977because, unlike the low molecular weight hydrophobic proteins, SP-A
and SP-D are multimeric glycoproteins and consequently impose
potential immunologic hazards. Economically synthesizing or reco-
vering human SP-A from natural sources is difﬁcult. Thus, the host
protective beneﬁts of these proteins are lost. The content of the
hydrophobic proteins (SP-B and SP-C) in different surfactant prepara-
tions varies but can be signiﬁcantly lower than the endogenous
surfactant. For instance, Survanta contains only ∼1/8 SP-B and ∼1/2
SP-C found in the endogenous bovine surfactant [177]. Curosurf
contains only ∼1/3 SP-B and ∼1/2 SP-C found in the endogenous
porcine surfactant [177]. The in vitro surface activity of different
animal-derived surfactants and their sensitivity to inhibition vary
signiﬁcantly [177,178], presumably related to the different protein
contents of these products.
As a result of different animal sources (bovine or porcine) and
different production procedures (bronchoalveolar lavage or lung
mincing), the modiﬁed natural surfactants differ not only in their
protein contents but also in the compositions of PL (especially DPPC,
PG and PI), neutral lipids (mainly cholesterol), and additives (such as
the palmitic acid and triacylglycerol supplemented in Survanta). A
detailed comparison of lipid and protein compositions of the modiﬁed
natural preparations can be found in a recent review by Blanco and
Perez-Gil [179]. The different PL contents can result in a signiﬁcant
difference in the ﬂuidity of different preparations and hence different
behavior of adsorption. The neutral lipids and additives likely play an
important role in altering the surface rheological properties of
different clinical preparations [180,181]. It should be noted that
despite the evident biophysical differential and clinical superiority of
some animal-derived surfactants over others, statistical differences in
mortality or days in neonatal intensive care units related to different
surfactant preparations have not been demonstrated [174–176].
Another limitation of animal-derived surfactants is the relatively
high cost, at approximately US$500 per dose for premature infants
[182]. These costs are mainly associated with the high expense of
conducting quality control with relatively small batches of biologi-
cally-derived products and recovery costs for the very expensive
clinical trials that must be conducted. When treating ARDS patients,
large surfactant amounts, multiple doses and a continuous supply will
be required. This will further increase the cost of surfactant therapy.
Socioeconomic analysis shows that surfactant replacement therapy is
only cost-effective in developed countries [182]. In the developing
countries, surfactant therapy is used only sparingly due to the lack of
an affordable clinical surfactant and the costs associated with
intensive care facilities. For instance, RDS affects 7–12% of newborns
in India and is associated with a high mortality rate due to the lack of
tertiary care, including surfactant treatment [183]. In China, surfactant
therapy has been introduced into clinical practice but only limited to
the highly developed regions of the country [184]. The high cost of
surfactant has prevented its worldwide distribution for neonates and
considerably more so for adult therapy. Thus, there is an urgent need
for developing an inexpensive surfactant preparation.
A new generation of clinical surfactants is under development
[185–189]. These preparations are fully synthetic and contain
synthesized surfactant protein analogs. The long-term goal of this
research is to develop synthetic surfactant preparations that fully or
closely mimic the biophysical properties of the endogenous surfactant
and highly resist inactivation. Mass production could result in a more
reasonable price. Both preclinical and clinical trials have been
conducted using synthetic surfactants with the addition of simpliﬁed
SP-B/C-like peptides.
The initial surfactant protein mimic studied was KL4, a short
amphipathic peptide consisting of leucine amino acids with a lysine
moiety introduced at every ﬁfth residue. This structure is based on a
positively charged helical segment of SP-B [190]. KL4 enhances the
adsorption of DPPC/PG/palmitic acid mixtures and interestingly, low
levels of SP-A further augment this adsorption [191]. Recent studieshave demonstrated that KL4 can promote formation of lipid protru-
sions with DPPC/DPPG mixtures [192]. Although KL4 exhibits a
number of interesting SP-B-like properties, it is still considered a
ﬁrst generation protein mimic. The manner in which this peptide
replicates SP-B properties is still being investigated [192–194].
Nevertheless, KL4 is being used as the basis of a wholly synthetic
surfactant, Surfaxin, which has been reported to be efﬁcacious with
premature infants and in preliminary studies with ARDS [195–197].
Another wholly synthetic surfactant is Venticute, a preparation
based on recombinant human SP-C (rSP-C), which has been utilized in
a number of clinical trials. Venticute is presently being investigated in
a trial involving direct lung insult-induced ARDS [198–201].
While the advantages of synthetic surfactant peptides are obvious,
synthesizing fully functional analogs of hydrophobic surfactant
proteins is unfortunately not a trivial task. The SP-B molecule is too
large and structurally complex to be easily synthesized. Folding this
hydrophobic protein to generate the three intra- and one inter-
disulphide bonds has proven particularly arduous. The palmitoylated
cysteine residues in SP-C have been replaced by phenylalanines.
However, SP-C molecules are structurally unstable in pure form and
tend to aggregate. A major goal of such research is to generate
“designer” surfactants with properties particularly well suited for
ARDS and other speciﬁc lung diseases. So far, none of the synthetic
preparations available have proven more efﬁcacious than the natural
preparations [176,189]. In addition, the presence of potentially danger-
ous reaction side-products and the possibility of adverse metabolic
effects related to intracellular processing of synthetic compounds
must be considered.
Nevertheless, it is important to note that signiﬁcant progress is
being made in this direction. Waring and associates have generated
a number of simpliﬁed SP-B analogs such as mini-SP-B (contains
N-terminal and C-terminal sections of SP-B) which mimic the
biophysical and physiological properties of the whole hydrophobic
protein [202,203]. Barron and coworkers have produced a number of
peptoids with SP-B and SP-C-like properties [204,205]. Such com-
pounds would have the advantage of being protease resistant. A
number of recent reviews offer in-depth discussion of these novel
approaches [185–189,206,207].
3.2. Surfactant inhibition
Surfactant inhibition, or inactivation, refers to those processes that
decrease or abolish the normal surface activity of PS. Such processes
may interfere with the PL adsorption to form a functional surfactant
ﬁlm, prevent the ﬁlm from reaching low γ upon compression, or affect
re-spreading of PL during expansion. A number of substances have
been reported to inhibit PS. The major inhibitory factors include
plasma proteins, unsaturated membrane PL, lysophospholipids, free
fatty acids, meconium (fetal feces expelled during stress), and
supraphysiological levels of cholesterol [11,14]. Surfactant inhibition
can also arise from degradation of surfactant lipids by phospholipases
or of surfactant proteins by proteases. These degradative agents,
normally present in the alveolus at very low levels, can be increased
duringmicrobial infection andmore importantly through secretion by
leukocytes and type II cells with pulmonary inﬂammation [208–211].
In addition to the above, surfactant can be compromised by reactive
oxygen species [212,213] and by pollutants [214,215] but these latter
effects will not be covered here.
3.2.1. Surfactant inhibition by plasma proteins
Leakage of plasma proteins into the alveolar space due to an
impaired alveolar-capillary barrier is an early event in the pathogen-
esis of ARDS [208]. The mechanism by which PS is inactivated by
plasma proteins is not yet fully understood. Evidence is available
demonstrating that albumin, ﬁbrinogen, and hemoglobin can inhibit
PS by competitive adsorption [216–221]. These protein inhibitors are
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water interface by spontaneous adsorption. Although larger than
individual PL molecules, these protein molecules are water soluble
and hence can quickly reach the interface by molecular diffusion. In
contrast, the insoluble PL of PS adsorb to the air–water interface by
cooperative diffusion of large molecular aggregates (essentially
vesicles), followed by vesicle “unzipping” and monolayer spreading
(see Section 2 for detail). Consequently, the protein molecules can
adsorb to the air–water interface quicker than the surfactant PL. Once
adsorbed, the protein ﬁlm excludes the PL from entering the interface
by creating a steric and/or electrostatic energy barrier [222,223]. In
keeping with this view, surfactant injected under preformed protein
ﬁlms adsorbs slowly and takes longer to reach low γ during
compression–expansion cycling [218]. Surfactant inhibition due to
competitive adsorption can be largely overcome in vitro by increasing
the surfactant concentration [220] or adding SP-A [130,224] because
these approaches enhance adsorption kinetics of PL.
Not surprisingly, surfactant inhibition depends on the plasma
protein/surfactant ratio [220]. The alveolar hypophase normally con-
tains only small amounts of soluble proteins [225–227]. For instance,
Rennard et al. [228] and Ishizaka et al. [229] have estimated the albumin
concentration in the epithelial lining layer to be 3.7 to 4.9 mg/mL,
corresponding to∼10%of theplasmavalues of albumin (i.e.,∼40mg/mL).
The concentration of PS in the alveolar hypophase has been estimated
to be 30 mg/mL in rats and 100 mg/mL in rabbits [230], calculated on
the basis of surfactant PL recovery by lavage [231] and an average
alveolar lining layer thickness of 0.2 μm [49,232]. Since inhibition
normally requires a much larger amount of protein than surfactant
[220], it appears that normal lungsmaintain a considerable safety factor.
However, in ALI/ARDS, the alveolar space experiences markedly
increased concentrations of plasma proteins, due to capillary leakage,
with average levels of 25mg/mL and individual values of over 100mg/
mL being reported [229]. (The high values, above plasma levels,
probably arise during epithelial recovery when ions and water are
eliminated more rapidly than proteins [225]). In contrast, the concen-
trations of surfactant PL and/or surfactant associated proteins decrease
due to inﬂammation, oxidation and simple dilution [208,233]. Conse-
quently, competitive adsorption may play a role in inactivating surfac-
tant under these circumstances.
Although considerable effort has been directed toward studying the
effects of plasma proteins on surfactant adsorption, it should be
stressed that these proteins can inhibit surfactant function in other
ways. Warriner et al. demonstrated that albumin interfered with re-
spreading of a model surfactant PL mixture, DPPC/POPG/palmitic acid
[221]. This inhibition occurswhenγ of 50mN/mor higher are attained,
where 50 mN/m corresponds to the γeq of albumin. This implies that
only when γ rises to the equilibrium for albumin can this protein
adsorb and interfere with PL re-adsorption/re-spreading. This is con-
sistent with the inability of albumin to inhibit high levels of surfactant
[220] and with the ability of DPPC, spread onto albumin ﬁlms to a low
γ, to displace this protein from the interface [234,235]. Nevertheless, it
should be noted that themodel PL systemdescribed above [221] did not
contain SP-B or SP-C, either of which tends to maintain the surfactant
ﬁlms near a γ of 25 mN/m, i.e., the γeq of PL. Unless inactivated, the
hydrophobic surfactant proteins would protect the ﬁlm against
attaining the high γ required for this inhibition mechanism [236,237].
In addition to the above example, recent work has provided further
evidence that albumin may inhibit surfactant by mechanisms other
thanonly interferingwith surfactant PL adsorption. BothNMR [238] and
X-ray diffraction [239] studies suggested that albumin directly inter-
acted with PL bilayers of BLES. Such interactions thinned the PL bilayers
and altered the distribution and motion of PL in bilayers/monolayers.
AFM studies demonstrated that serum altered the microstructures of
BLES monolayers [240,241]. As recently revealed by AFM and confocal
ﬂuorescence microscopy, albumin can remain within the LE phase of
the PL of BLES up to a π of 40 mN/m, signiﬁcantly higher than the πe ofalbumin (i.e., ∼20mN/m) [241]. By remaining at the surface andmixing
with the surfactant ﬁlms, albumin increases the ﬁlm compressibility
and may also disturb the normal PL phase transition and separation
[241]. Such inhibitoryeffects cannot be effectivelymitigated by repeated
compression–expansion cycles in a Langmuir balance [241]. These
studies suggest new biophysical mechanisms for surfactant inhibition
due to plasma proteins, and possibly also indicate that surfactant–
protein interaction/binding may play a role in the inhibition process.
Investigations of surfactant inhibition have emphasized serum
albumin because at 35–50 mg/mL, it is the predominant plasma
protein, accounting for about half of the plasma proteins [242]. The
availability of cheap, highly puriﬁed albumin is a likely consideration.
However, it must be mentioned that albumin is a very weak inhibitor
compared to a number of other plasma proteins. For example, early
studies by Seeger's group demonstrated that ﬁbrin generated from
ﬁbrinogen by a variety of methods was considerably more potent than
albumin in inhibiting a variety of surfactant preparations [230]. This
mechanism appears to involve coagulation of surfactant PL and
protein molecules, resulting in the hyaline membranes for which RDS
was originally named [23].
Surfactant function is alsomarkedly hampered through interaction
with C-reactive protein (CRP) [243,244]. CRPwas originally discovered
through its ability to bind the polar phosphorylcholine groups of PC.
This binding and the corresponding inhibition can be blocked by
water-soluble phosphorylcholine. Simultaneous increases in CRP and
decreases in SP-A in the alveolar space are conditions associated with
ALI [245]. In contrast to albumin, CRP markedly inhibits surfactant
function at 50 wt/wt.% of the surfactant and this inhibitory effect
cannot be relieved by repeated compression–expansion cycling.
Recent studies suggested that CRP inhibits PS by ﬂuidizing the surfac-
tant PL ﬁlms, i.e., a completely different mechanism from the com-
petitive adsorption of albumin [246,247]. As will be discussed shortly,
this mechanism is commonly associated with surfactant inhibition by
unsaturated lipids. As in the case of albumin and ﬁbrinogen, adding
SP-A at low levels relative to surfactant blocks the inhibitory effects at
a fraction of the inhibitory plasma proteins' concentration [246,247].
The mechanism by which SP-A reverses CRP-inhibition appears to be
also different from the case of albumin. It was suggested that direct
interaction between SP-A and CRP was responsible for preventing
inhibition due to this serum protein [246,247]. As discussed above,
however, SP-A overcomes albumin-induced inhibition mainly by
enhancing surfactant adsorption.
3.2.2. Surfactant inhibition by lipids
Although not nearly as well studied as protein inhibition, a second
inhibition mechanism involving unsaturated membrane PL, lysopho-
spholipids, free unsaturated fatty acids (such as oleic acid), bile acids,
diacylglycerol and cholesterol has been identiﬁed [248–251]. Some of
these lipids have detergent properties and can be referred to as
soluble amphipathic lipids because they form micelles [252]. None of
these lipids are bilayer formers, although they can be incorporated
into bilayers to some degree. Lysophospholipids are PL containing a
single fatty acid chain per molecule and are generated by phospho-
lipase A2 secreted by white blood cells and likely type II cells,
particularly during ALI and ARDS [253]. Bile acids, which are strong
detergents, are present in meconium, along with a number of other
lipids, mucous glycoproteins [254], and phospholipases [255]. Such
lipid substances can be considered diluents of the speciﬁc surfactant
lipid assembly. Thus, insertion and mixing of these unsaturated
amphipathic lipid and fatty acid molecules with the surfactant PL
molecules would signiﬁcantly ﬂuidize the PL monolayers and could
promote early collapse, thus preventing low γ from being reached.
The inactivation due to lipid penetration cannot be effectively over-
come by raising surfactant concentration [220,248,249].
Cholesterol is a special case of lipid inhibition since it is not very
amphipathic. Cholesterol appears to be an inherent component of
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which have been examined contain 5–10 wt.% (10–20 mol%)
cholesterol [74,256–258]. Cholesterol is also present in premamma-
lian vertebrates where it can reach very high levels [256]. Although
cholesterol has been associated with surfactants for a very long time,
phylogenetically, and its presence in mammalian surfactants has long
been recognized, the precise physiological role of this steroid in
surfactant remains somewhat ambiguous.
Early studies on model membranes and PS extracts revealed that
the presence of cholesterol tended to decrease ﬁlm stability at low γ
[73,128], presumably due to the increased ﬂuidity of the LO phase (see
Section 2 for the description of PL-cholesterol phase behavior). For this
reason, methods were developed for removing cholesterol from BLES
and Curosurf [73,84]. These observations were apparently related to
the use of the Langmuir balance and the PBS, which will be described
in Section 4. More recently, studies with the CBS have demonstrated
that the levels of cholesterol in natural surfactant and its lipid extracts
do not inhibit surfactant biophysical activity when assayed with this
device [251,259,260]. This difference is attributed to the lack of edge
effects (i.e., barriers, walls, and capillary) which make the CBS less
susceptible to the loss of PL from the air–water interface (i.e., so-called
“ﬁlm leakage”, detailed later in Section 4).
While cholesterol at 5–10 wt.% had no negative effects on surfactant
function with the CBS, a large number of studies have demonstrated
supraphysiological levels are detrimental [163,251,258,260,261]. Eleva-
tions in surfactant cholesterol have been reported in a number of animal
models of ARDS such ashigh-stretch ventilation-inducedALI [262], oleic
acid-induced ALI [263] and oxidant-induced ARDS [264]. Elevated
cholesterol has also been detected with ARDS patients due to fat
embolism syndrome [265]. A recent randomized, controlled clinical trial
found a remarkably elevated level of neutral lipids, including diacylgly-
cerol, triacylglycerol, and cholesterol, in the bronchoalveolar lavage
ﬂuids of patients with ARDS arising from various predisposing factors
[201].
Although the mechanism of cholesterol-induced inhibition has not
been fully elucidated, several groups, including our own, have demon-
strated alterations of surface-derived ﬁlms using AFM [163,260,261].
In particular, the ability to generate DPPC-rich condensed domains
within the LO/LD phase and to generate PL multilayers (surfactant
reservoirs) appears impaired with the addition of high levels of
cholesterol. Whether these two surface aspects of surfactant function
are related has not been clearly established.
The detrimental effects of high cholesterol on surfactant func-
tion raise the question as to whether it should be included in the
synthetic and semi-synthetic clinical preparations currently being
formulated, or removed from those modiﬁed natural surfactants
which contain this steroid. Bernardino de la Serna et al. [266] sug-
gested that small amounts of cholesterol may play a crucial role in
phase separation in porcine surfactant bilayers by inducing the
formation of Lo and Ld phases. Malcharek et al. [261] found phy-
siological levels of cholesterol (10 mol%) stabilize DPPC/DPPG/SP-C
ﬁlms by strengthening the surface-associated multilayer structures.
Nevertheless, to date, the authors know of no negative effects of
omitting cholesterol from clinical surfactants, although admittedly
the verdict is clearly still out. Since high levels of cholesterol are
clearly deleterious, it would appear judicious to avoid including
cholesterol in clinical preparations. This would build in a potentially
important safety factor by providing a sink for the elevated endoge-
nous sterol.
3.3. Overcoming surfactant inhibition
Overcoming inhibition will play a key role in developing new
surfactant formulations for ARDS treatment. Two general approaches
to be discussed here are (1) optimizing lipid and protein contents, and
(2) using water-soluble polymers as surfactant additives.3.3.1. Optimizing lipid and protein contents
Simply increasing the PL concentration of surfactant preparations
can effectively reverse plasma protein-induced inactivation [220]. It
was reported that increasing surfactant concentration also mitigated
meconium-induced inactivation [267]. As a new direction in optimiz-
ing the lipid components of surfactant, Notter and coworkers have
developed a novel surfactant preparationwhich consists of a synthetic
C16:0 diether phosphonolipid (DEPN-8) in combination with 1.5 wt.%
puriﬁed bovine SP-B/C [268] or mini-SP-B [269]. Compared to the
glycerophospholipids in other surfactant preparations, DEPN-8 is
structurally resistant to phospholipase degradation [268]. This
synthetic surfactant was found to be highly resistant to inhibition
due to serum proteins, phospholipase A2, and lyso-PC, both in vitro
[268] and in excised rat lungs [270]. A potential advantage of this
preparation is that, being resistant to phospholipases (A1, A2, and D),
DEPN-8 could be cycled into lamellar bodies and secreted back into the
alveolus without degradation. This would greatly prolong the effec-
tiveness of this synthetic preparation. A potential problem might be
that this synthetic lipidmay not be routed in the samemanner as DPPC.
However, the presence of signiﬁcant quantities of 1-alkyl ether PCs in
marsupial surfactants, particularly the Tasmanian devil [70], indicates
that ether lipids are compatiblewith normal processing in type II cells.
Optimizing the content of surfactant proteins is another effective
means to reverse inactivation. The superior performance of modiﬁed
natural surfactants over protein-free synthetic surfactants clearly
demonstrates the importance of SP-B and SP-C in overcoming surfac-
tant inactivation. Addition of peptide analogs of SP-B and/or SP-C also
improves the resistance to surfactant inactivation [202,203,271,272].
Adding SP-A to lipid extract surfactants increased their resistance to
inactivation due to blood proteins [130,224] and meconium [273]. In
vitro experiments showed that small amounts of SP-A can signiﬁ-
cantly enhance adsorption and dynamic surface activity of lipid
extract surfactants, thereby increasing their effectiveness at reduced
PL concentrations [129,131,274]. In animal experiments, surfactants
containing SP-A [275,276] showed higher resistance to inactivation
than the surfactants without SP-A.
3.3.2. Using polymeric additives
Taeusch et al. [277] and Kobayashi et al. [278] ﬁrst introduced the
concept of using low-cost, water-soluble, nonionic polymers, such as
dextran and polyethylene glycol (PEG), as additives to clinical PS. The
beneﬁts from these polymeric additives were found to be twofold
[279–281]. First, they can improve the surface activity of dilute
surfactant preparations (mainly by enhancing adsorption) and hence
are capable of decreasing the cost of surfactant therapy. Second, they
can effectively counteract surfactant inactivation due to a variety of
inhibitory substances (such as plasma proteins and meconium), thus
having a potential to enhance the clinical efﬁcacy of surfactant therapy
in treating ARDS.
The polymers tested so far cover a surprisingly broad range, includ-
ing nonionic (e.g., PEG [277] and dextran [278]), anionic (e.g., hyal-
uronan [282]) and cationic (e.g., chitosan [283]) polymers. Many in
vitro [222,277,278,282–290] and in vivo animal studies [278,291–297]
have shown that these polymers can signiﬁcantly improve the surface
activity of different clinical surfactants and reverse surfactant
inactivation. The encouraging results from these preclinical studies
make these polymers very promising for the development of low-cost
and inactivation-resistant surfactant formulations.
The increasing experimental success led to exploration of the
underlying mechanism responsible for the enhancement. These poly-
mers are hydrophilic. Alone they have no or only poor surface activity
[283,288].Whenmixedwith the inhibitory substances, such as albumin,
they do not alter the interfacial properties of the inhibitors signiﬁcantly
[283]. Therefore, it is unlikely that these polymers enhance surface
activity by directly accumulating at the interface or reverse inactivation
by directly interacting with the inhibitors. Yu et al. [288] found that
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surfactant preparations as a function of both polymer concentration and
molecular weight. These experimental results ﬁt very well with a
polymer-induced depletion–attraction model.
Depletion–attraction is a non-speciﬁc, polymer-induced entropic
force dependent on both the concentration andmolecular weight of the
polymer [298,299]. Depletion–attraction forces are routinely used to
promote fusion of cells in culture likely by the same mechanism that
improves surfactant function. The simpliﬁed model described here will
be followed byamore rigorousmathematical formulation. Consider two
surfactant vesicles approachingeachother. At a certainpoint the smaller,
non-deformable polymer molecules will no longer ﬁt in the space
available between the vesicles and so will be excluded (i.e., depleted)
from this space. The resulting enrichment in areas other than the region
between the two vesicles produces an increase in osmotic pressure in
those regions. This increased osmotic pressure draws water from the
polymer-depleted region, thus forcing the two vesicles together (i.e.,
attraction). The initial effect will be to promote membrane–membrane
(bilayer) fusion or aggregation. The resulting larger vesicles/aggregates
will be even further subject to depletion–attraction forces because they
are more effective in eliminating the polymer between them. A similar
process will occur at the air–water interface and the resultant depletion
forces will drive the vesicle towards the interface, thus decreasing the
energy barrier for surfactant adsorption. It should be noted that some
nonionic polymers such as PEG (10 kDa) may adsorb to the air–water
interface due to a weak surface activity (γeq of ∼60 mN/m [288]). This
may weaken the depletion forces near the surface region (personal
communication with Dr. Tonya Kuhl, UC Davis).
In physicochemical terms, the depletion forces described above arise
when two surfaces approach each other closely in a solution of non-
adsorbing polymers. As shown in Fig. 5, when the distance between theFig. 5. Schematic representation of the polymer-induced depletion–attraction mechanism
applies to non-adsorbing polymers such as low and mediummolecular weight polyethylene
a vesicle approaches the air–water interface, at a surface-to-surface distance nomore than tw
molecules are depleted since otherwise the polymer coils lose conﬁguration entropy. Con
depletion zone. The osmotic effect will drawwater away from the depletion zone, thereby gen
“pushes” the lipid aggregates to the air–water interface. As indicated by the interaction pote
depletion can be as large as the van der Waals force in the absence of the polymer. The protwo surfaces/vesicles decreases to approximately two times the radius of
gyration of thepolymer chains (2Rg), thepolymermolecules in the region
between these two surfaces are depleted since otherwise the polymer
coils lose conﬁguration entropy, i.e., they will be deformed or involved in
other randomchanges inmorphology. Consequently, anosmoticpressure
appears between the bulk solution that contains the polymer and the
polymer depletion zone of radius Rg between the two surfaces. The
osmotic effect generates a net force of attraction between these two
surfaces and hence causes ﬂocculation. Kuhl et al. [300,301] have
provided solid evidence that depletion–attraction is responsible for the
fusion of pure PC vesicles in PEG solutions by direct force measurements
using a surface force apparatus. They also found a change from attraction
to repulsion with increasing molecular weight of PEG [300,302]. This
turnabout was due to adsorption of PEG molecules onto the surfaces of
the PC vesicles, which eliminates depletion–attraction but raises steric
repulsion between the vesicles [302]. A similar turnabout has been
reported when BLES was mixed with a high molecular weight PEG
(300 kDa), where surfactant adsorptionwas completely abolished [288].
The depletion force can be quantitatively estimated from the
classical model ﬁrst developed by Asakura and Oosawa [303]. When
considering the depletion force between two ﬂat surfaces, this model
can be simpliﬁed as follows [304].
The depletion pressure (P) between two ﬂat surfaces is:
P = −qkT ð2Þ
where ρ is the molecular density of the polymer, i.e., the number of
molecules per unit volume (m−3); ρ=6.022 ×1029 CW/MW, where Cw
and Mw are the polymer concentration (wt.%) and molecular weight,
respectively; k is the Boltzmann constant, 1.38×10−23 (J/K); T is the
absolute temperature (K).in promoting surfactant aggregation and adsorption. Note that this mechanism only
glycol (PEG). The depletion forces arise when two vesicles approach each other, or when
o times the radius of gyration of the polymer chains (2Rg). In these regions, the polymer
sequently, an osmotic pressure appears between the bulk solution and the polymer
erating a net force of attraction between these two vesicles. This causes ﬂocculation and
ntial — vesicle-to-vesicle distance (E–D) curve, the attraction force due to PEG-induced
ﬁles of interaction potentials with/without PEG are adapted from Kuhl et al. [300].
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region D at Db2Rg is:
E Dð Þ = −
Z 2Rg
D
qkTdD = −qkT 2Rg−D
 
= E0 1−D= 2Rg
  
: ð3Þ
At contact of the two surfaces (i.e., at D=0)
E0 = E 0ð Þ = −2RgqkT : ð4Þ
To relate the interaction potential between two ﬂat surfaces to the
adhesion force (F) between two identical spheres of radius R, one can
use the Derjaguin approximation, which gives:
F Dð Þ = pRE Dð Þ: ð5Þ
Substituting Eq. (4) into Eq. (5), gives




Eq. (6) predicts the polymer-induced depletion–attraction force (F)
between twovesicleswith a similar size to beproportional to the vesicle
radius (R), polymer size (Rg), polymer concentration (Cw), and tempera-
ture (T), and inversely proportional to the molecular weight of the
polymer (Mw). Strictly speaking,Rg in Eq. (6) should be replacedwith the
thickness of the depletion layer, which can be experimentally estimated
from the distance between two approaching vesicles when they start
experiencing the attractive force [300]. In addition, Cw in Eq. (6) should
be replaced by the activity at high polymer concentrations.
Using Eq. (6), it is estimated that PEG (Mw=8 kDa, Rg=5 nm) at a
concentration of 50mg/mL (Cw=5wt.%) can induce a depletion force of
∼50 pN in a colloidal system of vesicles with an average radius of
100 nm at 37 °C. This force is in the same order of magnitude as the
contribution of van derWaals attraction that is always present even in
an aqueous suspension free of polymers [300]. Although being an
extremely simpliﬁedmodel, the depletion forces predicted fromEq. (6)
were found to correspond very closely to those directly measured
using a surface force apparatus [300]. More complicated calculations
resulted in no signiﬁcant deviation from this simpliﬁed model [300].
Zasadzinski et al. [223] have developed a more detailed thermo-
dynamic model to study the mechanisms of surfactant inactivation
due to serum proteins and to explain how polymers such as PEG
overcome this inactivation by depletion–attraction. Using the classical
Smolukowski analysis of colloid stability, this theoretical model con-
ﬁrmed that the polymer-induced depletion force promotes adsorption
of PL vesicles/aggregates of PS, thereby overcoming competitive ad-
sorption of serum proteins. This model predicts that the adsorption
rate of PL vesicles/aggregates increases only linearly with the bulk
surfactant concentration but exponentially with decreasing the
energy barrier for adsorption [223]. Hence, the use of water-soluble
polymers appears to provide a very effective and inexpensive way to
overcome surfactant inactivation.
The depletion–attraction model predicts that adding nonionic
polymers would alter the surfactant morphology in the bulk phase,
i.e., inducing larger surfactant vesicles/aggregates with the depletion
forces. Morphological alterations of surfactant due to the presence of
inhibitors and/or polymers were evident under optical microscopy
[223,283] and transmission electron microscope (TEM) [267,305,306].
Optical microscopy detected that PEG added to different clinical sur-
factant preparations induced large aggregated structures [223]. Using
Cryo-TEM, Gross et al. [305] found thatmeconium altered themorphol-
ogy of Curosurf from spherical unilamellar andmultilamellar vesicles to
smaller and elongated structures with nonuniform curvatures. At high
magniﬁcations, these workers observed disruption of PL vesicles when
Curosurf was mixed with meconium or taurocholic acid, a bile acid inmeconium. This may indicate that meconium inhibits surfactant in part
by penetrating the bilayer structures of the PL vesicles. Ochs et al. [306]
found that adding dextran into meconium-inhibited Curosurf reversed
the surfactant morphology from small, irregular structures to large
lamellar body-like, unilamellar and multilamellar structures. Together
with the reversal of surfactant morphology, the surface activity of
Curosurf was also restored [306]. All of these observations suggest a
correlation between morphology of surfactants and their surface
activity, which is consistent with the biophysical analysis of surfactant
subfractions (detailed in Section 4) [307–309].
It should be stressed that the surfactant morphology – surface
activity correlation discussed above appears to be only valid for
surfactants mixed with nonionic polymers, where depletion–attrac-
tion is the major driving force for ﬂocculation of PL vesicles.
Surfactants with the addition of ionic polymers such as hyaluronan
do not necessarily follow this rule. Both freeze-fracture TEM [310] and
turbidity [290] studies found that low-concentration hyaluronan
did not induce as much aggregation as high-concentration PEG but
enhanced surface activity more. This indicates that ionic polymers
enhance surface activity of surfactants by a different mechanism than
the nonionic polymers (detailed later).
3.3.3. Beyond surface activity enhancement
The use of water-soluble polymers as additives to clinical PS could
potentially break new ground in the development of cost-effective,
inactivation-resistant formulations that are highly favorable for ARDS
treatment. The early in vitro tests mainly focused on the improvement
in surface activity, i.e., rapid adsorption, low γmin upon compression,
and high resistance to surfactant inactivation. However, recent studies
suggest that a number of further considerations beyond surface
activity enhancement will be necessary for further development.
First, the efﬁcacy of different polymers seems to be dependent on
the clinical surfactant to which the polymer is added. Lu et al. [292]
found that both in vitro and in vivo dextran was more effective when
mixed with Curosurf while PEG was more effective when mixed with
Survanta. The speciﬁcity of a polymer for a certain surfactant
preparation may imply a speciﬁc molecular interaction between the
polymeric additive and certain PL/protein components which are
varied in different surfactant preparations. If such a speciﬁc interac-
tion does exist, the depletion–attraction mechanism needs to be
amended as, theoretically, depletion–attraction ought to be non-
speciﬁc. In addition, this means that the experimental results obtained
from one polymer-surfactant combination may not necessarily be
generalizable to the others.
Second, the performance of a polymer may depend on the speciﬁc
experimental approach used for evaluation. It has been shown that
different lung injury models yield different alveolar environments
that can play a critical role in determining the overall efﬁcacy of the
surfactant therapy [311]. Lu et al. found that PEG (10 kDa) signiﬁcantly
improved the efﬁcacy of surfactant therapy in meconium-induced
[295], acid-induced [294], and endotoxin-induced [294] animal ARDS
models. However, Campbell et al. [312] reported an adverse effect of
PEG in a saline lung lavage model. With these latter studies, rabbits
treated with mixtures of BLES and PEG showed greater hypoxemia,
lower lung compliance, and higher hypercapnia compared to those
administered only BLES. The deleterious effects of PEG in the saline
lung lavage model were conﬁrmed by a different group using a
different animal (rats) and a different surfactant (Survanta) [313].
These deleterious effects were attributed to increased pulmonary
edema due to the addition of PEG which has a high capacity to bind
water. In the saline lung lavage model, this side-effect of PEG can
overwhelm its beneﬁcial effects on enhancing surface activity. These
negative reports constitute a serious caveat to the use of polymers as a
surfactant additive.
In addition, it should be noted that most previous in vitro studies
involving polymers used serum proteins (usually albumin), whole
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shown that PEG cannot effectively overcome surfactant inhibition due
to supraphysiological levels of cholesterol [314]. These experimental
results, on the one hand, are consistent with the argument that PEG
overcomes surfactant inhibition mainly by enhancing surfactant
adsorption, which has been compromised in the presence of plasma
proteins. On the other hand, these results also show the inability of
PEG to deal with surfactant inhibition by lipids, such as cholesterol,
which inhibit surfactant by a completely different mechanism. Given
the fact that cholesterol may play a signiﬁcant role in ARDS [201,315],
the clinical potential of the polymeric additives in treating ARDS is still
to be conﬁrmed.
Third, polymer dosing has not always been optimized. A PEG
(10 kDa) concentration of 50 mg/mL was recommended in a number
of early studies [277,294,295]. However, it has been reported that a
much lower concentration near 20 mg/mL was sufﬁcient to render a
satisfactory surface activity in vitro [285,288]. Further increasing PEG
concentration yielded no apparent improvement in surfactant
adsorption [288]. Similarly, a much lower concentration of hyaluronan
than previously used [282,293] was found to be sufﬁcient to produce
satisfactory performance both in vitro and in vivo [291]. High polymer
concentrations can introduce difﬁculty in drug delivery due to
increased viscosity [283,297], increased osmotic stress in the lungs
[313], and possible impaired pulmonary gas exchange due to reduced
gas diffusivity in the alveolar lining layer [316]. Hence, it is necessary
to optimize the polymer dosing relative to the particular in vivo
situation.
The difﬁculty in endotracheal instillation due to viscous surfactant
preparations may be mitigated to some degree by using a new
approach of drug delivery, i.e., bronchoalveolar lavage with a large
volume of dilute surfactant. A recent study has shown that a mixture
of 10 mg/mL Curosurf and 30 mg/mL dextran (69 kDa) improved
meconium clearance and lung function in rabbits with meconium
aspiration [296]. Compared to bolus delivery, bronchoalveolar lavage
with dilute surfactant–polymer mixtures may help to directly remove
inhibitors from the alveolar space and facilitate drug delivery. Another
study showed that dextran improved the efﬁcacy of Curosurf given at
a low dose but not at a high dose in a lung injury model induced by
tracheal instillation of albumin [297]. This further demonstrates the
negative effect of increased viscosity on the efﬁcacy of surfactant
formulations.
Finally, the use of ionic polymers with PS clearly requires
considerably more investigation. Ionic polymers are superior to
nonionic polymers in requiring lower effective concentrations.
Hyaluronan (1240 kDa), an anionic biopolymer inherently existing
in the alveolar ﬂuid, was able to prevent serum-induced surfactant
inactivation at a concentration 40 times lower than that of PEG
(10 kDa) (1.25 mg/mL vs. 50 mg/mL) [222]. Chitosan (612 kDa), a
cationic biopolymer derived from fully or partially deacetylated chitin,
was shown to enhance the surface activity of dilute BLES and to
reverse albumin-induced inactivation at a concentration 1000 times
lower than PEG (10 kDa) (0.05 mg/mL vs. 50 mg/mL) [283,289]. The
reduced polymer concentration facilitates drug delivery and mini-
mizes osmotic stress in vivo. In spite of these advantages the
mechanisms by which the ionic polymers interact with PL of PS are
still vague. When the added polymer moieties are polyelectrolytes, a
combination of electrostatic interactions and polymeric effects (such
as depletion–attraction) is expected [283,289,290]. At extremely low
concentrations, however, the polymer-induced depletion force (as
predicted by Eq. (6)) would be weak and only secondary to the
electrostatic interactions. Moreover, if the ionic polymers adsorb to
the surface of PL vesicles by non-speciﬁc electrostatic binding, the
depletion force would be more or less eliminated. Although direct
experimental evidence for PS is still lacking, studies of pure PL vesicles
[317,318] and monolayers [319,320] both suggested that chitosan
interacted with PL mainly through electrostatic interactions.When using ionic polymers as surfactant additives, it is also
important to keep in mind that the introduced electrostatic interac-
tions may disturb the charge balance in surfactant. It was found that
the effects of chitosan and hyaluronan on the surface activity of BLES
were critically dependent on the polymer-to-PL ratio [283,289]. Above
the optimal range of this ratio, i.e., at higher polymer concentration, an
inhibitory effect on surface activity was observed [283,289]. These
ﬁndings are consistent with previous reports that addition of
polycations could inactivate surfactant as a function of the cationic
additives-to-surfactant PL ratio [321,322]. Determination of the
optimal ratio in vitro appears to require characterization of the pH
and ionic strength of the electrolytes, especially the calcium
concentration [289]. The ratio dependence of the ionic polymers
complicates the surfactant formulation and would be best, if not only,
tested using in vivo animal models (see Section 4).
To conclude Section 3, it has become apparent that, compared to
ALI and ARDS, surfactant treatment of premature infants with RDS is
relatively straightforward. One must simply recognize the signs that
signiﬁcant RDS is imminent and administer surfactant before serious
lung injury occurs. This explains why the relatively poor protein-free
synthetic surfactants employed in early trials were beneﬁcial. They
merely had to provide sufﬁcient surfactant PL substrate to mix with
endogenous alveolar pools of surfactant and/or cycle through the
developing type II cells to maintain infants until they could generate
sufﬁcient endogenous surfactant of their own. Nevertheless, establish-
ing surfactant therapy for neonates with basically healthy lungs took
many years.
ARDS has clearly proven much more difﬁcult. Part of the reason
that ALI and ARDS are so difﬁcult clinically is the lack of appropriate
early markers for identifying those patients whose disease will not
resolve spontaneously. Further difﬁculty arises from the multiple
insults involved in lung injury and surfactant inhibition. Early pilot
trials with infants clearly demonstrated the futility of introducing
surfactant into lungs ﬁlled with surfactant inhibitors and this led to
early treatment protocols with RDS. For a number of reasons,
including the lack of dependable markers and expense, pulmonolo-
gists do not have the option of treating ARDS early and in practice are
almost always faced with multiple inhibitory mechanisms arising
from the original insult and including membrane and lysopho-
spholipids as well as various plasma proteins. In addition there is
the release of proteases, phospholipases and other disruptive agents
from lung tissue. To give one example, it has been shown that lyso-PC,
at levels which do not affect the biophysical activity of surfactant,
sensitizes surfactant to protein inhibition [249]. Another example is
meconium aspiration syndrome, which involves many inhibitory
agents including bile acids, fatty acids, proteins and other substances
[14,173,250,323]. Under these circumstances, surfactant function will
be inhibited by both competitive adsorption and ﬁlm penetration and
likely some other mechanisms. Consequently, the actual mechanism
of inhibition in the case of ARDS can be expected to be quite
complicated due to additive and synergistic effects of different
inhibitors [324]. Different biophysical mechanisms of surfactant
inhibition have been summarized in Fig. 6.
As it stands, overcoming inhibition will play a crucial role in the
development of clinical surfactants for ARDS treatment. The use of
low-cost, water-soluble polymers as surfactant additives has proven
to be a promising approach in this direction. The early studies focused
on the nonionic polymers, such as dextran and PEG. These polymers
likely contribute to improving surface activity and overcoming
inhibition by plasma proteins through a depletion–attractionmechan-
ism. However, generating a large enough depletion force to enhance
surfactant adsorption requires high concentrations of these polymers,
thus introducing difﬁculties in tracheal drug delivery and causing
increased osmotic stress in the lungs. More recent studies exploit the
ionic polymers, such as hyaluronan and chitosan, which require a
much lower effective concentration than the nonionic polymers.
Fig. 6. Biophysical mechanisms of surfactant inhibition by different inhibitors. Different
inhibitors, including plasma proteins and certain lipids, can (A) interfere with the PL
adsorption to form a functional surfactant ﬁlm at γeq of ∼23mN/m; (B) prevent the ﬁlm
from reaching low γmin of ∼0 mN/m or increase ﬁlm compressibility upon ﬁlm
compression; and (C) affect PL re-spreading from surfactant reservoirs to obtain γmax of
∼30 mN/m upon ﬁlm expansion. (A) Soluble proteins such as ﬁbrinogen, ﬁbrinogen
monomer, hemoglobin, and albumin interfere with de novo surfactant PL adsorption to
equilibrium [112,130,178,201,217–220,222–224,230,249,272,282,324–330]. Surfactant
adsorption is also markedly impaired by lyso-PC [283,314,112,220,327–329] and lyso-
PG [249,324,329]. However, supraphysiological levels of neutral lipids such as
monoacylglycerol, diacylglycerol, unsaturated fatty acids, cholesterol, and cholesterol
ester show little or no effect on adsorption [201,251,327]. (B) The ability of surfactant PL
to attain low surface tensions during compression is hampered by total serum proteins,
ﬁbrinogen, ﬁbrinogen monomer, CRP, and to a lesser extent, by albumin [241,244,314].
Surfactant compressibility is markedly increased by supraphysiological levels of
cholesterol [163,251,260]. Surface tension reduction is also affected by high mono-
acylglycerol, diacylglycerol, unsaturated fatty acids, and cholesterol esters [201]. (C) Re-
spreading of surfactant PL from surface-associated reservoirs is inhibited by CRP and, at
high surface tensions, by albumin [221,244]. Supraphysiological levels of cholesterol
also have a deleterious effect on surfactant re-spreading [163,260]. The re-spread ﬁlms
are thought to be very similar, if not identical, to de novo adsorbed ﬁlms described in
(A). Only small amounts of the surfactant ﬁlms are lost during each cycle and equivalent
amounts of PL are taken up through de novo adsorption.
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surfactant function and resistance to inhibition is still unclear.
Considerable attention should be given to the negative reports of
using polymers in animal trials. A number of in vitro studies have also
demonstrated adverse effects of adding polyelectrolytes to surfac-
tants, depending on the polymer-to-PL ratio. Taking into account the
difﬁculty in controlling a ﬁxed polymer-to-PL ratio, before and after
drug delivery, we suggest that in vivo animal trials are crucial for
testing the polymeric additives, especially the ionic polymers.
4. Methods for evaluating pulmonary surfactant
Methods for assessing the surface activity of PS fall into three
categories: in vivo, in situ and in vitro techniques.
4.1. In vivo methods
As discussed in Section 2, a functional surfactant must be able to
rapidly form a surface ﬁlm at an air–liquid interface and to reduce γ to
very low values under dynamic compression. When exogenous
surfactant is administered to a surfactant-deﬁcient lung, these
biophysical characteristics should translate into lung compliance
and, as a consequence, improved blood oxygenation. However, the invivo situation is more complicated since the physiological response is
not only determined by the biophysical properties of the surfactant,
but also by how this material is delivered to the terminal airspaces and
how it is metabolized once deposited [331]. For this reason evaluation
of newly developed exogenous surfactants utilizing in vivo experi-
mental models is critical prior to clinical usage of such preparations.
These in vivo methods contribute ﬁrst-hand physiologically relevant
information on the factors inﬂuencing surfactant therapy, such as the
efﬁcacy of different surfactant preparations, the effects of different
means of administration, dosing and timing, etc.
Various in vivo models have been developed to evaluate the
efﬁcacy of surfactant replacement therapy on preterm and term
animals. Accordingly, the commonly used in vivo models can be
generally divided into those primarily involving surfactant deﬁciency,
such as the premature animal model and the saline lung lavage model
in adult animals, and those primarily involving surfactant dysfunction
or inactivation, such as the meconium aspiration, high-stretch ven-
tilation, and acid aspiration models [332,333]. The overall objective of
the latter models is to investigate the therapeutic potential for the
speciﬁc lung injury rather than an examination of the biophysical
properties in vivo. As such, a detailed discussion of those studies
is beyond the scope of this review and we will focus solely on the
surfactant-deﬁcient models.
Evaluation of surfactant efﬁcacy in premature animals has been
performed mainly with premature rabbits [273,334–336]. In these
experiments the rabbit fetuses are delivered by caesarean section at a
gestational age of 27 or 28 days, at which time the lungs are still
surfactant-deﬁcient. The premature rabbits are connected to a pres-
sure controlled ventilator in a 37 °C plethysmography setup in which
the peak pressure at which each rabbit is ventilated can be controlled
individually. Surfactant can be administered directly into the lungs of
the animals though a bolus injection via an endotracheal tube. The
main outcome of surfactant efﬁcacy in this model is dynamic lung
compliance during ventilation.
The two main advantages of the preterm rabbit model are the size
of the preterm rabbit lung which ensures optimal surfactant
distribution throughout the lung with a relatively simple instillation
procedure, and the ability to rapidly performmeasurements on a large
number of animals simultaneously. Disadvantages include the rela-
tively short period of observation which does not allow for detailed
metabolic assessments of the exogenous surfactant, and limited
ﬂexibility in terms of ventilation strategy during the analysis. This
model has been utilized extensively to test exogenous surfactant,
including studies comparing the efﬁcacy of different surfactants,
testing protein inhibition and examining the physiological activity of
different surfactant subtypes [273,334–336].
A second preterm animal model that has been utilized is the
premature lamb [337,338]. Although conceptually similar to the
preterm rabbit model, this model has the advantage of a larger animal
sizewhichmore closelymimics the premature infant observed in RDS.
This model allows for more extensive measurements on blood gases,
surfactant distribution, and metabolism. On the other hand, the
premature lamb is considerably more labour-intensive and expensive.
In general, this model is suitable for more extensive preclinical studies
for exogenous surfactant therapies.
The saline lavage model in adult animals has also been utilized
extensively for testing surfactant preparations [309,339–343]. In
general, this method involves connecting the animal to a mechanical
ventilator and subsequently lavaging the lung with saline to remove
the endogenous surfactant. One response to the lavage procedure will
be the secretion of intracellular surfactant; thus the lavage procedure
is repeated several times at regular intervals. Depletion of surfactant is
generally reﬂected by low blood oxygenation, and can be conﬁrmed by
analysis of the amount of surfactant removed by the ﬁnal lavage
procedure. Subsequently, exogenous surfactant can be administered
to the surfactant-deﬁcient animal. The most relevant physiological
Fig. 7. Schematic of a Langmuir–Wilhelmy balance (LWB). The surfactant ﬁlm is usually
formed by spreading at the air–water interface of the aqueous subphase ﬁlling the
Langmuir trough. Moving the barrier to the right decreases the area of the spread ﬁlm,
thereby increasing surface pressure (i.e., decreasing surface tension, according to Eq. (1)).
The surface tension is determined by measuring the change in the vertical pull on the
Wilhelmy plate.
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oxygenation. The animals can be monitored for several hours which
may reﬂect how the surfactant is handled in the airspace.
The adult saline lavage model has been employed in a large variety
of species including rats, rabbits, pigs and sheep. In general, smaller
species are utilized for simple comparisons between different
surfactant preparations. Larger animal models may also test efﬁcacy
of surfactant preparations, but more often are utilized for other
aspects that inﬂuence the surfactant therapy such as the delivery
method or the effects of ventilation strategy after treatment.
In general, most in vivo studies examining the activity of surfactant
have conﬁrmed the previous in vitro data. For example, in vitro
analysis of the biophysical activity of the different surfactant sub-
fractions, i.e., the large aggregates (lamellar bodies, multilamellar
vesicles, tubular myelin) and small aggregates (small unilamellar
vesicles), indicated that the large aggregates represented the func-
tional component of surfactant [307]. This was subsequently con-
ﬁrmed in vivo utilizing both the premature rabbit and the lavage rat
models [309,335]. In another study Bailey et al. utilized lavaged rats to
compare the physiological responses to an exogenous surfactant
(BLES) with and without exposure to oxidation [339]. This study
conﬁrmed previous in vitro data that had demonstrated that oxidation
impaired the surfactant function [153,212]. Importantly however, not
all in vivo studies correlate with the in vitro biophysical activity. For
example, as part of the study mentioned above, Bailey et al. [344]
found that SP-A addition improved the biophysical activity of oxidized
BLES in vitro, but this combinationwas not as effective as control BLES
in vivo. Also, based on investigations in which the addition of PEG to
surfactant was able to improve the exogenous surfactant properties in
vitro, Campbell et al. [312] investigated this in the lavaged rabbit
model. In contrast to the in vitro data, animals receiving surfactant
with PEG had an inferior physiological response compared to animals
receiving just surfactant. A subsequent study suggested that the
administration of PEG in this model led to increased extracellular lung
water thereby limiting its functionality (see also Section 3) [313].
4.2. In situ methods
Two in situ methods have been developed to estimate alveolar γ in
excised lungs. One is the pressure–volume (P–V) method initially used
by von Neergaard [22] in his early discovery of the importance of
alveolar γ forces. This procedure was also used by Mead et al. [26],
followed by standardization by Fisher et al. [345], Bachofen et al.
[121,346] and Wilson [347,348]. This method indirectly determines
alveolar γ by analyzing the P–V isotherms of excised lungs ventilated
in a quasi-static manner. The principle of this method is as follows:
inﬂating or maintaining the lungs at a ﬁxed volume with air requires
work against both tissue forces and γ forces. Filling the lungs with
saline annihilates the air–liquid interface, thus leaving only the lung
tissue forces. Hence, the difference between the P–V isotherms of air-
ﬁlled and saline-ﬁlled lungs reﬂects the contribution of γ forces. In
practice, this procedure is complicated by the need to remove all air
from the lungs. This can be achieved by allowing the lungs to collapse
completely. For instance, this can be aided by brief ventilation with
pure O2 which, in contrast to N2-containing air, can be completely
absorbed by the vasculature.
Another in situ method is the microdroplet technique ﬁrst
developed by Schurch and coworkers [28,119,120,349] in the 1970s.
This is so far the onlymethod truly capable of direct γmeasurement in
the lung. With this method, a droplet of a water-immiscible liquid
(e.g., ﬂuorocarbon) with known γ is deposited onto the alveolar
surface of excised lungs using a micropipette. The droplet will spread
on the surfactant lining layer of the alveoli to form a liquid lens.
Theoretically, the equilibrium shape of this lens (its contact angle) is
determined by the balance of γ of the three adjacent interfaces, i.e.,
air–lens liquid, air–lining layer, and lens liquid–lining layer interfaces,as predicted by the classical Neumann triangle relation [116]. Hence,
the shape of the liquid lens can be used to estimate γ of the surfactant
lining layer. In practice, the alveolar γ is estimated from the diameter
of the liquid lens, monitored by amicroscope. A calibration curve (γ vs.
diameter of the lens) for the immiscible ﬂuid is determined in a
separate in vitro experiment using a Langmuir balance. It should be
noted that this calibration procedure may introduce errors into the in
situ γmeasurements [350]. This is because the shape and diameter of
the liquid lens is determined by the surface tension balance only for a
sufﬁciently deep subphase. If the thickness of the subphase is similar
to the penetration depth of the liquid lens, the lens can be signiﬁcantly
distorted by a disjoining pressure [351]. Consequently, the γ-diameter
curve calibrated in a Langmuir balance, with a macroscopic subphase,
could deviate from the in vivo situation, where the aqueous
hypophase of alveoli is extremely thin (i.e., ∼0.2 μm, see Section 2).
The microdroplet method has also been successful applied to mea-
sure γ in vivo, for example, in the trachea of non-anesthetised horses
[352].
4.3. In vitro methods
Because of their convenience, in vitro methods are most commonly
used for examining the surface activity of PS. A variety of techniques
have been developed for this purpose. Three widely used methods are
the Langmuir–Wilhelmy balance, pulsating bubble surfactometer, and
captive bubble surfactometer. In addition to these three, amethod called
the constrained sessile drop was recently developed for the in vitro
assessment of PS. These four methods will be extensively discussed and
compared.Other invitromethodswill alsobe introduced, albeit inmuch
lesser detail. Other reviews on the three traditionally used in vitro
methods are also available [14,84,104,105,353,354].
4.3.1. Langmuir–Wilhelmy balance
The classical Langmuir balance was introduced to surface science
in the early years of the 20th century [118]. An insoluble surfactant
monolayer, usually in organic solvent, is spread on top of a liquid
subphase, usually aqueous, ﬁlling a trough. The ﬁlm is conﬁned by two
barriers that move symmetrically, or by a ﬁxed one on one side and a
movable one on the other side. The ﬁlm can be slowly compressed and
expanded in a quasi-static fashion by the relative movement of the
two barriers. The force acting on the ﬂoating barrier is measured by a
horizontal force transducer, which directly indicates π. Clements
[27,355–357] modiﬁed Langmuir's original design to introduce the
Langmuir–Wilhelmy balance (LWB) to the study of PS. As shown in
Fig. 7, the LWB consists of a Langmuir trough constructed of Teﬂon and
aWilhelmy plate for measuring γ of the ﬁlm-covered subphase. Recall
that π and γ are coupled by Eq. (1) (see Section 2).
Fig. 8. Schematic of a pulsating bubble surfactometer (PBS). The polyacrylamide chamber
ﬁlled with the sample (∼20 μL) to be tested is positioned on the pulsating unit. Sufﬁcient
ﬂuid is withdrawn by the pulsator such that the sample water level moves down through
the capillary and a bubblewith Rmin is created. The pressure difference across the bubble is
recorded for 10 s to monitor surfactant adsorption, and this is reported as surface tension
(according to Eq. (7)). The bubble is then pulsated between Rmin and Rmax at 20 cycles/min
while surface tension is recorded. The inset illustrates ﬁlm leakage, i.e., spreading of the
surfactant ﬁlm to the water layer remaining inside the capillary during bubble formation.
The leakage can beminimized by keeping the capillary dry. However, the effect of leakage
can be augmented when studying surfactant inhibition due to plasma proteins as these
proteins can adsorb onto the capillary during bubble formation and these proteins, being
hydrophilic, retain water, thus impeding drainage.
1965Y.Y. Zuo et al. / Biochimica et Biophysica Acta 1778 (2008) 1947–1977This early tensiometric apparatus not only initiated a virtual
explosion in surfactant research (Section 2), but also remains popular
even now. The LWB is well suited for recording π-area isotherms of
spread monolayers as the surface area per molecule can be precisely
determined by controlling the amount of surfactant spread and the
surface area available for spreading. This feature is particularly useful to
characterize the surface rheological properties of individual PS
components and their simple mixtures. Another primary advantage of
the LWB is the capability for easy combination with a variety of
microscopic and spectroscopic techniques [358], which are not readily
amenable to the other in vitro methods. Such assemblies allow direct
examination of molecular structure, orientation, domain formation,
topography, electrical surface potential, and localized chemical compo-
sition of either surfactant ﬁlms at the air–water interface or ﬁlms
transferred to a solid substrate using the Langmuir–Blodgett technique.
The LWB has been used in conjunctionwith Brewster angle microscopy
[143,146,359], ﬂuorescence microscopy [63,142,143,146,167,359], con-
focal microscopy [87,360], scanning near-ﬁeld optical microscopy
[361,362], AFM [63,149,157,166,241,363–365], grazing incidence X-ray
diffraction [364,366], infrared spectroscopy [367,368], sum-frequency
generation spectroscopy [369,370], and ToF-SIMS [152,156,260]. Appli-
cation of these ﬁlm imaging/analysis techniques to PS studies has
provided valuable information that complements the traditional
tensiometry techniques.
In spite of the above merits, the LWB has a number of drawbacks for
studying PS. First, it is not ideal for studying surfactant adsorption from
the subphase as it requires a relatively large amount of liquid sample, i.e.,
usually no less than several tens of millilitres. Second, the LWB only
allows relatively slow compression–expansion cycles as fast cycling
creates waves at the air–water interface, which interfere with the γ
measurement. Together with the difﬁculties in precisely controlling the
physiological temperature and humidity, the LWB does not directly
simulate respiration. Third, there can be a problem with the measure-
ment accuracy of the Wilhelmy plate as it requires a 0° contact angle
between thevertical dippingplate and theadherentﬂuid layer [116]. This
condition can be difﬁcult to maintain, especially during ﬁlm expansion,
since the PLmolecules tend to adsorb onto the plate during the previous
ﬁlm compression [371]. While these concerns can be overcome with
careful work, they make the LWB a challenging apparatus to operate
accurately. Finally, a less obvious but serious problem, the LWB can suffer
from a phenomenon known as “ﬁlm leakage”. Film leakage is driven by
thermodynamics: at sufﬁciently low γ, surface active material tends to
spread fromtheair–water interface onto the solid framework supporting
the ﬁlm, i.e., wetting of the solid barriers and walls, as this process
decreases the total free energy of the system [372]. Leakage of PL at the
air–Teﬂon surface usually starts at γ of ∼18 mN/m [353,372]. Due to the
loss ofﬁlmmaterial from theair–water interface, theapparentmolecular
area and ﬁlm compression ratio can be erroneous. Also because of ﬁlm
leakage the ability to reach low γ can be greatly compromised.
With the LWB, ﬁlm leakage may occur both at the trough walls and
at the barriers, either above the water level (at the air–solid interface)
or below the water level (at the liquid–solid interface) [353]. Leakage
at the barriers can be reduced using tightly ﬁtted barriers [357] or
continuous Teﬂon ribbons [355,373]. Leakage at the trough walls can
be reduced by priming the Teﬂon walls with an alcoholic solution of
lanthanum chloride and long-chain saturated PC [96]. Using these
treatments, near-zero γ can be achieved by extreme ﬁlm compression.
A constant π, however, can normally only be maintained by pro-
gressively compressing the ﬁlm, demonstrating that the LWB fails to
reproduce the extraordinary ﬁlm stability found in situ [119]. The
problems in ﬁlm stability are particularly evident at physiological
temperature and humidity [96,374,375].
4.3.2. Pulsating bubble surfactometer
The pulsating bubble surfactometer (PBS) was ﬁrst introduced by
Enhorning in 1977 [376]. As shown in Fig. 8, the currently commer-cially available PBS consists of an air bubble formed in a disposable
polyacrylamide chamber. The chamber contains only 20 μL of the test
liquid and is immersed in a temperature-controlled bath. The bubble
is formed by drawing air from the atmosphere through a capillary
(bubble-on-a-tube model). Adsorption is monitored for 10 s. Subse-
quently, the bubble is oscillated by a pulsator between two ﬁxed
positions: a minimum radius of 0.4 mm and a maximum radius of
0.55 mm, which produces a maximum 50% reduction in surface area.
The cycling frequency usually used is 20 cycles/min to mimic
breathing. However, it can be changed from 0.02 to 80 cycles/min.
During oscillation, the maximum and minimum radii (R) of the
bubble are monitored by a microscope. The pressure gradient across
the bubble (ΔP) is measured by a pressure transducer. Since the
bubble communicates with the ambient atmosphere, the pressure
gradient measured by the transducer corresponds to the negative
pressure across the liquid phase. γ is calculated using the Laplace





The PBS is highly efﬁcient and time-effective. One measurement
can be completed within 5 min and takes only ∼20 μL of sample.
Therefore the PBS has been widely used for the quality control of
clinical surfactants. In addition, it is superbly useful for monitoring
and comparing the surface activity of different surfactant samples
when many animal or clinical samples are generated. The rapid
adsorption during expansion is indicated by the γ of the ﬁlm at the
maximum bubble radius and the ability to reach low γ is examined
when the ﬁlm is compressed to the minimum bubble radius. Another
advantage of the PBS, which makes it superior to the LWB, is the fast
pulsating rate that permits direct simulation of breathing.
Nevertheless, the PBS has some drawbacks. First, for a number of
reasons, leakage is a serious problem. At low γ leakage can occur at
both the inner surface (air–solid) and outer surface (liquid–solid) of
Fig. 9. Schematic of a captive bubble surfactometer (CBS). The captive bubble ﬂoats
against the hydrophilic ceiling but is separated from it by a thin wetting ﬁlm. This
prevents the ﬁlm leakage normally encountered at low surface tension with other
surface balances. The inset shows multilayer structures of the adsorbed pulmonary
surfactant at the air–water interface of the bubble. The surface tension is determined by
bubble shape analysis (according to Eq. (8)). Surface area manipulations are conducted
by altering the hydraulic pressure in the chamber.
1966 Y.Y. Zuo et al. / Biochimica et Biophysica Acta 1778 (2008) 1947–1977the capillary. The original PBS reported by Enhorning used home-
made chambers with a Teﬂon capillary which reduced leakage onto
the air–solid interface [376]. With the present polyacrylamide
chamber, a thin ﬁlm of water can be retained inside the capillary
when the bubble is formed, thus leading to a much greater ﬁlm area
than anticipated (see the inset in Fig. 8). During pulsation, the water
ﬁlm can drain from the capillary but this can be variable [377]. For
example, plasma proteins can adsorb onto the capillary during bubble
formation and the proteins, being hydrophilic, retain water, thus
impeding drainage. Hence, it is particularly problematic with studies
of surfactant inhibition by plasma proteins where the apparent
deleterious effects of these proteins can be augmented in the PBS due
to leakage. Also because of leakage, the PBS is not suitable for studying
ﬁlm stability at γmin in a non-pulsating mode.
A secondproblemwith the commercial PBS is the lack ofﬂexibility in
assessing the surface activity. For example, the time for adsorption to
equilibrium is set at 10 s. While this can be changed, it cannot be done
easily. As a result, animal and clinical samples are subject to expansion
and contraction, often before γeq is attained. This obviously has an
impact on γmin and γmax, as well as γeq recorded for that particular
sample. Lengthening the adsorption time would also help to minimize
the amount of water remaining inside the capillary and therefore ﬁlm
leakage. In addition, the way that the current commercial apparatus
functions is to initiate pulsation by expanding the bubble from the
minimum radius at the end of the 10 s adsorption period. Thus, even if
the sample has attainedγeq, an additional 50% of area is imposed in 1.5 s
(for pulsating at 20 cycles/min), making it impossible to relate initiation
of compression to γeq. Moreover, although additional information can
be accessed, the PBS usually records only the γ of the bubble at the
maximum and minimum radii, to be the γmax and γmin, in a pulsating
mode. The maximum reduction of bubble area, i.e., the compression
ratio, is ﬁxed at 50%, which prevents detailed study of surface rheology.
Finally, γmeasurements at low values using Eq. (7) are not reliable.
Even for a small bubble less than 1 μL (∼1 mm in diameter), the
assumption of spherical shape does not hold true when the γ falls to
values near 1 mN/m [378]. The effect of gravity on bubble deformation
at low γ and other effects of altering the bubble shape such as the
hydrodynamic effects due to rapid pulsating have been extensively
studied by Franses and coworkers [379–381]. Nevertheless, it should
be stressed that in most situations where this apparatus is used to
compare functional vs. non-functional surfactants, the estimations of
γmin are more than adequate [378].
A recent development by Seurynck et al. [382] contributes to
improving the current PBS. A real-time image acquisition system has
been integrated into the traditional PBS, which allows the determina-
tion of γ and surface area at any point of pulsating. In addition, instead
of simply assuming a spherical shape, these workers ﬁt the bubble
proﬁle to an ellipse. This yields enhanced accuracy compared to
spherical ﬁtting. Although still incapable of preventing ﬁlm leakage,
the real-time imaging facilitates visual detection of ﬁlm leakage into
the capillary. Those images with leakage can be discarded in data
processing.
4.3.3. Captive bubble surfactometer
The captive bubble surfactometer (CBS) was ﬁrst introduced by
Schurch et al. in 1989 [383]. As shown in Fig. 9, an air bubble (2–7 mm
in diameter) is introduced into a chamber where it ﬂoats against a
ceiling coated with 1% agar gel. The agar coating renders the ceiling
completely hydrophilic. Consequently, the bubble is separated from
the ceiling by a thin wetting ﬁlm of the surrounding aqueous liquid,
thus avoiding adhesion to any solid support and apparently eliminat-
ing all potential pathways for ﬁlm leakage [384]. It should be noted
that the use of the agar coating is not always necessary provided that
the ceiling is smooth and hydrophilic. It has been shown that a
chamber made of stainless steel without the agar coating is also
capable of maintaining a leakage-proof environment [385].The original CBS chamber was constructed from a gastight syringe
making it very difﬁcult to spreadﬁlms so that only adsorbedﬁlmswere
studied [383,384]. More recently, different ﬁlm spreading techniques
have been developed for the CBS [386,387]. With one spreading
technique developed by Putz et al. [386],ﬁlms are spread fromorganic-
extracted surfactants onto the bubble surface with a microsyringe,
followed by exhaustive subphase replacement to remove the organic
solvent vapor. Another type of spreading technique was developed by
Schurch et al. [387]. Films are spread/adsorbed at the bubble surface
from an aqueous suspension of high-concentration surfactant using a
microsyringe. To ensure the surfactantﬂoats around the bubble surface
to enhance spreading, the saline subphase can contain 10wt.% sucrose,
which increases the density of the subphase.
Afterﬁlm formation, the bubble can be compressed and expanded in
either quasi-static or dynamic fashion by varying the hydraulic pressure
in the chamber. The pressure can be changed by varying the chamber
volume [383] or by regulating liquid ﬂow between the chamber and an
external reservoir (with the manufactured plastic chamber) [388]. The
frequency of cycling can be varied from extremely slow (i.e., in the case
of quasi-static cycling) to faster than 60 cycles/min.
In contrast to the PBS, the shape of the bubble in the CBS cannot be
assumed to be spherical due to its relatively large size. (See Fig. 10(a)
and (b) for two typical captive bubble imageswith different γ.) Instead,
the bubble shape is controlled by the mechanical balance between













where R1 and R2 are the two principal radii of curvature at the studied
point on the surface, which reﬂect the shape of the bubble; R0 is the
radius of curvature at the apexof the bubble;Δρ is the density difference
across the interface; g is the local gravitational acceleration; z is the
vertical distance from the apex to the studied point. Normalizing Eq. (8)






The Bond number reﬂects the relative effects of gravity and
capillary forces on the shape of a drop/bubble. Hence, it is possible to
determine γ from the bubble shape since gravity is known. Oneway of
characterizing γ from the bubble shape is to use the height-to-diam-
eter ratio of the bubble, as formulated by Malcolm and Elliott [389].
Bubble area and volume can be calculated from polynomial functions
Fig. 10. Typical images of captive bubble (CB), constrained sessile drop (CSD) and pendant drop (PD) at different surface tensions. (a) CB at 21 mN/m; (b) CB at 1.3 mN/m; (c) CSD at
47 mN/m; (d) CSD at 0.68 mN/m; (e) PD at 42 mN/m; (f) PD at 16 mN/m. The black particles in the CB images are insoluble surfactant aggregates suspended in the subphase, which
introduce optical noise to the images. The arrow in (a) points at a satellite bubble formed during the experimental manipulations, which can have a very deleterious effect on the
surface tensionmeasurement. Arrows in the CSD and PD images point at the three-phase contact line. The three-phase contact line in (f) is not discernable due to ﬁlm leakage. The PD
and CSD images are courtesy of Ms. Zdenka Policova, University of Toronto.
1967Y.Y. Zuo et al. / Biochimica et Biophysica Acta 1778 (2008) 1947–1977regressed from measurements of a series of sample bubbles with a
wide range of height-to-diameter ratios [390].
A more accurate and automatic way to determine γ, surface area
and volume from a bubble image is to use axisymmetric drop shape
analysis (ADSA). ADSAwas ﬁrst developed byNeumann and associates
in the 1980s [391]. ADSA has been continuously improved during the
last two and a half decades [392–394]. Conceptually, ADSA determines
γ by numerically ﬁtting the shape of experimental drops or bubbles to
the theoretical proﬁles given by the Laplace equation of capillarity
(Fig. 11). The input parameters of ADSA are g, Δρ, and a number of
coordinates of the experimental drop/bubble proﬁle automatically
detected by digital image analysis. ADSA was ﬁrst applied to analyze
captive bubble images by Prokop et al. [385]. A new generation of
ADSA has been recently developed [394–396]. By using advanced
image analysis, this new ADSA is capable of automatic γ measure-
ments of turbid ﬂuids, such as PS in which optical noise is introduced
by insoluble surfactant aggregates and sometimes satellite bubbles
(see Fig. 10(a) for an example). This new ADSA was found to be
particularly useful for studying surfactants with polymeric additives
where system turbidity increases (see Section 3 for detail) [394–396].
Strictly speaking, determination ofγ from the shape of a drop/bubble
is only applicable to an equilibrium condition since the Laplace equation
(Eq. (8)) considers only the balance between the gravity and capillary
forces. Under a highly dynamic condition, such as dynamic cycling in the
CBS, the bubble proﬁle may deviate from the theoretical proﬁle
predicted by the Laplace equation due to hydrodynamic effects (suchas inertial and/or viscous effects caused by ﬂuid ﬂow). This may intro-
duceerrors inγmeasurementusingADSA. Liaoet al. have systematically
studied the hydrodynamic effects on the measurement of dynamic
γ using an oscillating bubble [380,381]. Results from the numerical
simulation suggested that the hydrodynamic effects were negligible
except at some extreme conditions, such as a highly viscous liquid
oscillated at an extremely high frequency. For a bubble in aqueous
media, only if the oscillatory frequency is slower than 10 Hz (i.e.,
600 cycles/min) will the bubble proﬁles predicted from ADSA and from
the model considering the hydrodynamic effects be in good agreement
[381]. The effects of viscous forces on ADSA measurement were also
studied by Freer et al. [397]. Similarly itwas found that the viscous forces
were only signiﬁcant enough to alter the ADSAmeasurement for highly
viscous liquid upon highly rapid dynamic oscillation.
The CBS has been used to measure adsorption rate (time to
equilibrium), γmin, and γmax, during quasi-static or dynamic compres-
sion–expansion cycling, and the percent of area reduction required to
attain γmin from γmax. The percentage of area reduction has been
shown to be a more sensitive parameter than γmin in evaluating
surface activity of PS, especially in the study of surfactant inhibition. In
addition, owing to its leakage-proof capacity, the CBS is well suited for
studying mechanisms of surfactant ﬁlms, such as ﬁlm compressibility,
stability, and collapse at extreme π. For ﬁlms adsorbed at low surfac-
tant concentrations (0.2–0.5 mg/mL), near-zero γ can be readily ob-
tained by a moderate compression ratio (i.e.,b20% area reduction).
This is in good agreement with the in situ measurements. Studies of
Fig. 11. Principle of axisymmetric drop shape analysis (ADSA). ADSA measures surface
tension from the shape of pendant drops, sessile drops or captive bubbles by comparing
the experimental drop/bubble proﬁles (dots in the X–Z coordinate) with the theoretical
Laplacian curves (curve in the x–z coordinate). The experimental proﬁles are
automatically extracted from the drop/bubble images using advanced image analysis.
The theoretical Laplacian curves are generated by numerical integration of the Laplace
equation of capillarity (Eq. (8)). ADSAdetermines surface tensionby iterativelyﬁtting the
experimental proﬁle to a family of theoretical curves until the best match is found. The
best matched theoretical curve represents the experimental drop/bubble. ADSA solves
this optimization problem by minimizing an objective function that consists of the sum
of least squares of the minimum distance (i.e., normal distance, di) between the
experimental points and the theoretical proﬁles.With the input of the local gravitational
acceleration (g) and the density difference across the interface (Δρ) (see Eq. (9)), ﬁve
parameters can be simultaneously optimized: the surface tension (γ), the curvature at
the apex (1/R0), the coordinates of the apex of the experimental proﬁle (x0, z0), and the
verticalmisalignment (α). The surface area and volumeof the drop/bubble are calculated
from the surface of revolution of the best matched theoretical proﬁle. Adapted from del
Río and Neumann [393].
1968 Y.Y. Zuo et al. / Biochimica et Biophysica Acta 1778 (2008) 1947–1977ﬁlm stability in the CBS are commonly performed in two different
ways. Stability can be examined by compressing the bubble and hold-
ing the volume at a minimum value. A stable ﬁlm is able to maintain
the γmin (in an isovolumetric fashion) without returning towards
equilibrium for a prolonged period [307,374]. Similarly, stability can be
examined by studying the rate of bubble area reduction required to
maintain a constant γ, i.e., in an isobaric fashion [97,145]. Alterna-
tively, stability can be examined by studying “bubble clicks”, i.e., a
sudden decrease in bubble area associated with an increase in γ,
which indicates partial collapse of the surfactant ﬁlm coating on the
bubble surface [374,383]. Bubbles coated with a stable ﬁlm have less
tendency to click. The CBS is also ﬂexible in terms of being able to vary
independently the amount of ﬁlm compression (i.e., compression
ratio) and the speed of the compression (i.e., compression rate) [377].
Moreover, in conjunction with other techniques, the CBS is able to
scrutinize a variety of surfactant characteristics, such as the surface-
associated surfactant reservoir, using a subphase depletion technique
[60] and a subphase solidiﬁcation technique (solidiﬁcation of the
hypophase–surfactant lining complex in a sodium alginate solution by
adding calcium ions) [59]. In addition to γmeasurements, the CBS has
been broadly expanded to other investigations, e.g., gas transfer prop-
erties of PS ﬁlms [398,399], dissolution characteristics of anesthetic
vapors and gases [400].
A major advantage of the CBS is the ability to conduct investiga-
tions at physiological and higher temperatures. For example, with the
LWB it is difﬁcult to demonstrate that DPPCmonolayers can attain π of
70 mN/m (i.e., near-zero γ) at 37 °C [95,96] and relatively few studies
using this apparatus show π higher than 50 mN/m even at room
temperature, when the ﬁlms are compressed in a quasi-static fashion.
In fact, results from a number of LWB studies have concluded
that DPPC monolayers become unstable somewhat above 41 °C
[92–94,401], which of course corresponds to the main transition
temperature Tm for DPPC bilayers (detailed in Section 2). These
experimental studies suggested that PL monolayers might possess a
critical point. A critical point can be deﬁned as the temperature and
pressure above which the properties of two phases no longer remain
distinct. For example, above 31 °C and 73 atm, CO2 becomes
supercritical CO2, a ﬂuid which has the characteristics of both a liquidand a gas. However, more recent investigations using the CBS have
shown that spread DPPC monolayers melt between 48 and 53 °C and
found no evidence for critical behavior [97,145]. While the case for
critical behavior of PL monolayers depends on several arguments,
these melting data make this phenomenon considerably less certain.
In any event, such CBS studies emphasize the advantage of employing
this apparatus for experimentation under extreme conditions.
Nevertheless, the CBS also has weaknesses. First, in contrast to the
LWB, the γ and surface area (i.e., the bubble area) in the CBS is coupled.
This is due to the fact that the area of a bubble is a function of not only its
volume but also its shape as determined by the γ forces. When a
surfactant-coated bubble is compressed, the bubble volume decreases,
which tends to decrease the bubble area, and meanwhile, the γ
decreases, which tends to increase the bubble area [374]. Hence, it is
more difﬁcult to precisely control the bubble area than its volume in the
CBS. Nevertheless, in most cases this does not pose a serious concern
on the recorded γ-area isotherms because the apparent area at each
time is still calculated based on the same bubble image fromwhich γ is
estimated. Second, compared to the PBS, operation and data processing
of the CBS is relatively time-consuming. The problem of tedious data
processing can be largely solved using ADSA [394–396]. Third, for
adsorption studies, the maximum surfactant concentration is usually
restricted to no more than 3 mg/mL [58]. This restriction arises from
optical limitations since surfactant suspensions become murky and
eventually opaque at increased concentrations. High-concentration
surfactants can be studied using spreading techniques. Finally, the CBS
may not ensure full humidiﬁcation automatically. This concern arises
when the CBS is used to study surfactant adsorption inwhich the rapidly
adsorbed surfactant ﬁlms may present a barrier to water evaporation,
thus slowing down the process of humidiﬁcation [374]. Although direct
humidity measurements in the bubble are not yet available, there was
clearly a difference in the adsorption kinetics and ﬁlm stability of BLES
ﬁlms formed on bubbles of ambient air and prehumidiﬁed air [374,402].
4.3.4. Constrained sessile drop
The prototype of the constrained sessile drop (CSD) was ﬁrst
developed by Wulf et al. [403] for simultaneously measuring γ and
the density of polymer melts. It was later modiﬁed by Yu et al. [404] for
determining theγ of PS. As shown in Fig.12, a sessile drop (4∼8 μL) of PS
rests onapedestal,whichemploys a sharpknife-edge toprevent thedrop
from spreading, thus eliminating ﬁlm leakage. The pedestal is machined
from stainless steel with a diameter of 2.5 to 4 mm. The angle between
the horizontal and the lateral surfaces of the pedestal is 45° to 60°. The
pedestal has a central hole of 0.5 mm, through which the drop is
connected to a surfactant reservoir of 0.5–0.75 mL. The surfactant
reservoir is continuously stirred by a magnetic stir bar. Formation
and oscillation of the sessile drop is performed by a programmable
motor-driven syringe connected to the surfactant reservoir.
Film formation in the CSD can be conducted by adsorption or
spreading. For adsorption studies, a drop can be formed within 0.5 s,
which ensures adsorption at a fresh, clean air–water interface.
Spreading on the CSD from either aqueous solution or organic solvent
is also straightforward. After ﬁlm formation, the drop can be oscillated
at a predetermined compression ratio and compression rate, from
very slow to very fast.
The CSD facilitates rigorous atmospheric control by means of an
environmental control chamber. Full humidiﬁcation, monitored by a
hygrometer, is ensured by awater reservoir enclosed in the chamber. A
gas manifold system (to produce different gas compositions) and a gas
chromatography system (to analyze the gas composition) are under
development. This development aims at studying the effect of different
gas compositions on the surface activity of PS ﬁlms. It has been
reported that different gases, such as CO2 [405] and ﬂuorocarbon gases
[406,407], affected the surface activity of PS and PL ﬁlms.
So far, no apparent serious limitations have been found with the
CSD. This device eliminates both the problems of ﬁlm leakage, as in
Fig. 12. Schematic of a constrained sessile drop (CSD). The sessile drop is formed on a
pedestal that employs a sharp knife-edge (as shown in the inset) to conﬁne the drop
from spreading over, even at low surface tensions, thus preventing ﬁlm leakage. The
sessile drop is connected to a surfactant reservoir under constant stirring. Drop
formation and oscillation are performed by regulating outﬂow of the surfactant sample
in the reservoir using a computer-controlled motor-driven syringe. Surface tension is
determined by shape analysis (according to Eq. (8)). The entire setup is enclosed in an
environmental control chamber.
1969Y.Y. Zuo et al. / Biochimica et Biophysica Acta 1778 (2008) 1947–1977the LWB and PBS, and of concentration restriction, as in the CBS.
Compared to the CBS, the CSD is much simpler and easier to operate,
and requires a much smaller amount of liquid sample (i.e., only a few
microlitres for each measurement). The γ, surface area and drop
volume can be automatically computed by ADSA with a simpliﬁed
image analysis scheme taking advantage of the high-contrast edge of a
sessile drop image (Fig. 10(c) and (d)).
The CSD is very suitable for measuring the low γ of PS ﬁlms formed
by adsorption from a surfactant subphase at physiologically relevant
concentrations. Preliminary tests showed a good agreement betweenTable 3
Comparison of four in vitro methods for assessing the surface activity of pulmonary surfact
Methods Advantages Disadvantages
LWB • Precisely-controlled molecular areas for mixtures of
phospholipids
• Not readily adaptab
• Easy assembly with different surface analysis techniques • Difﬁcult to control
• Commercially available (e.g., Kibron Inc., Espoo, Finland;
KSV Instruments Inc., Helsinki Finland; Nima Technology
Ltd, Coventry, UK)
• Not capable of dire
• γ measured from a
• Film leakage at low




• Direct simulation of breathing • Film leakage at low
• Commercially available (General Transco, Inc., Largo, FL) • γ measured at low
CBS • Close simulation of alveolar environment • Difﬁcult to operate
• Leakage-proof capacity • γ and surface area
• Capable of studying both adsorbed and spread ﬁlms • Limitation on the m
studying adsorbed ﬁ
• Accurate and automatic γ measurement in conjunction
with ADSA
• Uncontrolled humid
• Commercially available (Department of Physiology and
Biophysics, University of Calgary)
CSD • Precisely-controlled experimental environment • γ and surface area
• Little sample consumption (in μL range) • Not yet commercia
• Leakage-proof capacity
• Capable of studying both adsorbed and spread ﬁlms
• Accurate and automatic γ measurement in conjunction
with ADSA
• Easy to operate and clean
• No limitation in surfactant concentration
LWB: Langmuir–Wilhelmy balance; PBS: pulsating bubble surfactometer; CBS: captive bubble
γ: surface tension.CSD and CBS measurements [404]. The CSD has been applied to a
variety of studies, such as the effect of humidity on ﬁlm formation and
cycling [375,402], and the development of polymeric additives for
clinical surfactants [283,289].
4.3.5. Other in vitro methods
In addition to the above four techniques, other in vitromethods are
available for assessing the surface activity of surfactants. For instance,
the surface activity can be examined by studyingmicrobubble stability
[408–410]. Enhorning and Holm developed a capillary surfactometer,
which is especially suitable for examining the role of surfactant in
maintaining airway patency [411]. This method has proven especially
useful for research involving asthma. Meier et al. [412] developed an
oscillating drop surfactometer in which a 1 μL pendant drop is
oscillated in resonance with an exciter. This method simultaneously
measures γ and energy dissipation at the surface, thus providing an
approach to evaluate surface viscosity. The γ is calculated from the
experimentally determined oscillation period by considering the
Rayleigh instability. However, this method is restricted to γmin of
∼15 mN/m, at which point the drop is released. Bertocchi et al. [413]
developed an inverted interface technique in which γ is estimated
from the curvature of a submicron-sized pendant drop. Combined
with ﬂuorescence microscopy, this method permits the study of
adsorption of single surfactant aggregates. However, this method does
not allow compression and expansion of the surfactant ﬁlms.
Neumann et al. [414] have developed a pendant drop (PD)
tensiometry system, which has been used in conjunction with ADSAant
Main applications
le for studying adsorbed ﬁlms • Study of surface rheological properties
of surfactant monolayers
the environment • Study of phospholipid phase behaviors
in conjunction with microscopic and
spectrometric methods
ct simulation of breathing
Wilhelmy plate may not be very accurate
γ
t lacks ﬂexibility in assessing surface • Quality control of clinical samples
γ • Rapid comparison of the surface activity
of many different samples
values are inaccurate
and clean • Study of surfactant mechanisms
are correlated • Comprehensive and accurate evaluation
of surfactant properties
ax. surfactant concentration when
lms
• Miniaturized Langmuir balance for
studying spread monolayers
ity when studying adsorbed ﬁlms • Study of gas transfer properties of
surfactant ﬁlms
are correlated • Study of high surfactant concentrations
at very low γ
lly available • Study of environmental effects (humidity,
gas composition, etc.) on surfactant
• Miniaturized Langmuir balance for
studying spread monolayers
surfactometer; CSD: constrained sessile drop; ADSA: axisymmetric drop shape analysis;
1970 Y.Y. Zuo et al. / Biochimica et Biophysica Acta 1778 (2008) 1947–1977for measuring surface activity of PS [288,402,415–417]. The PD
method features advantages of simplicity and high accuracy. However,
it suffers from ﬁlm leakage when γ of the surfactant ﬁlms is decreased
to ∼18 mN/m [385]. (See Fig. 10(e) and (f) for PD images at different γ.
Film leakage is shown in Fig. 10(f).) The PD is well suited for the study
of surfactant adsorption as the limitation of ﬁlm leakage is relatively
minor in such a case. As mentioned in Section 2, the γeq of PS ﬁlms is
approximately 22–25 mN/m, which is well above the threshold value
at which leakage may occur. Inspired by the CSD, a new PD method is
under development in which the traditional capillary is replaced by a
pedestal with a sharp knife-edge to prevent ﬁlm leakage. The pedestal
is similar to that used in the CSD but upside-down. Cabrerizo-Vilchez
et al. have further developed the ADSA-based PD technique by
introducing a novel coaxial capillary design for rapid subphase
exchange in a pendant drop [418]. With this development, the PD
can be used as a fully functional miniaturized alternative to the
traditional Langmuir balance for the study of insoluble PL ﬁlms.
In summary of Section 4, different in vivo, in situ, and in vitro
methods have been developed for the evaluation of biophysical
properties of PS. The in vitro methods outperform the others in terms
of convenience of operation and efﬁciency in collecting data. Among
the in vitro methods available, four tensiometry techniques, LWB, PBS,
CBS and CSD have exhibited full capacity to simulate and measure all
three important biophysical properties of PS, i.e., rapid adsorption, low
γmin upon ﬁlm compression, and limited γmax upon ﬁlm expansion.
The relative merits and disadvantages of these four methods are
summarized in Table 3. Selection of a speciﬁc method depends on the
measurements of interest and the desired accuracy.
5. Concluding remarks
After more than a half century of research, PS proves itself to
remain a “super extraordinary juice” [42] full of surprises. The most
attractive motivation for studying PS is perhaps its clinical applica-
tions. Though there is still room for improvement, such as the ongoing
development of fully synthesized designer surfactants, surfactant
therapy has been very successful in treating premature infants with
RDS. However, the applicability to ARDS, and other pulmonary
diseases such as asthma, has not clearly been established. Inactivation
of PS undoubtedly contributes to its unsatisfactory performance in
ARDS. In vitro biophysical studies led to two distinct inhibition
mechanisms: inhibition due to competitive adsorption of plasma
proteins, and inhibition due to mixing and ﬂuidizing an otherwise
stable PS ﬁlm by lipids. This simple classiﬁcation implies that the
former mechanism mainly inﬂuences surfactant adsorption while the
latter prevents the ﬁlms from reaching low γ. Recent studies using
direct ﬁlm imaging, however, have provided new evidence that the
actual inhibition mechanisms due to both proteins and lipids, such as
cholesterol, could be much more complicated. In addition, the exact
relevance of these inhibitionmechanisms to ARDS is still undeﬁned. In
ARDS, the endogenous and exogenous surfactants are likely to be
inactivated by multiple mechanisms. The predominant mechanisms
by which surfactant is inhibited in vivo are still unestablished.
We would suggest that overcoming surfactant inhibition plays a
central role in resolving the clinical constraints on surfactant therapy
in ARDS. The use of polymers as surfactant additives is an intriguing
approach due to its potent preclinical performance in resisting
inhibition and the simplicity in formulation, i.e., by simply mixing
water-soluble polymers with currently available surfactant prepara-
tions. However, it should be noted that the selection of a polymeric
additive and the determination of its optimal concentration require
consideration of physiological factors and not just surface activity.
Selection of an appropriate evaluation model representing clinical
practice, examination of the pulmonary ﬂuid balance and the
interfacial gas transfer properties, plus the ease of tracheal instillation
all need to be kept in mind for the preclinical tests. Some of theseconcerns can beminimized by using ionic polymers, which seem to be
effective at much lower concentrations than nonionic polymers.
However, introducing ionic polymers may disturb the electrostatic
balance in the PS system, which must be carefully considered.
Since Clements conducted the ﬁrst direct γ measurements of PS
using his home-made LWB half a century ago, many more in vitro
tensiometric techniques have been developed. These methods have
their own relative merits and disadvantages. Selection of a particular
method depends on the application and the desired accuracy. During
the last decade, in combination with the LWB, more and more surface
analysis techniques have been applied to studies of PS. Application of
these techniques opens new horizons to the study of PS. These tools
enable direct ﬁlm imaging on domain formation, topography,
molecular orientation, electrical surface potential, ﬁlm thickness,
and even localized chemical compositions. Combining γ measure-
ments with information obtained from direct ﬁlm imaging has
provided unprecedented insight into the behavior of PS, such as the
ﬁnding that pressure-driven phase transition/separation occurs in
surfactant monolayers, and that the formation of multilayer structures
from monolayers occurs at high π.
Progress has also beenmade in combining ﬁlm imaging techniques
with γ measurements using drop shape methods. It has proven
possible to directly apply ﬂuorescence microscopy [419] and even
scanning force microscopy [420] at the air–water interface of a bubble
with an adjustable size. Although limitations still prevent these
methods from acting as a fully functional miniaturized Langmuir
balance with in situ ﬁlm imaging capacity, it is not unreasonable to
foresee that such amini-balance-imaging assembly may be developed
soon. The CSD could provide a promising drop conﬁguration in this
direction as the air–water interface in the CSD is readily accessible to
microscopic facilities. With the aid of new techniques more insight
would be gained towards the biophysical understanding of PS and
eventually for the development of new inhibition-resistant surfactant
formulations for ARDS treatment.
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